-
1
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
2
-
-
84860792754
-
Role of the VEGF/VEGFR axis in cancer biology and therapy
-
Rapisarda, A.; Melillo, G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv. Cancer Res. 2012, 114, 237-267.
-
(2012)
Adv. Cancer Res.
, vol.114
, pp. 237-267
-
-
Rapisarda, A.1
Melillo, G.2
-
3
-
-
84866183545
-
Matrix metalloproteinases in vascular physiology and disease
-
Siefert, S.A.; Sarkar, R. Matrix metalloproteinases in vascular physiology and disease. Vascular 2012, 20, 210-216.
-
(2012)
Vascular
, vol.20
, pp. 210-216
-
-
Siefert, S.A.1
Sarkar, R.2
-
4
-
-
84863248391
-
The development of MetAP-2 inhibitors in cancer treatment
-
Yin, S.Q.; Wang, J.J.; Zhang, C.M.; Liu, Z.P. The development of MetAP-2 inhibitors in cancer treatment. Curr. Med. Chem. 2012, 19, 1021-1035.
-
(2012)
Curr. Med. Chem.
, vol.19
, pp. 1021-1035
-
-
Yin, S.Q.1
Wang, J.J.2
Zhang, C.M.3
Liu, Z.P.4
-
5
-
-
79953264876
-
Role of the cytoskeleton in formation and maintenance of angiogenic sprouts
-
Bayless, K.J.; Johnson, G.A. Role of the cytoskeleton in formation and maintenance of angiogenic sprouts. J. Vasc. Res. 2011, 48, 369-385.
-
(2011)
J. Vasc. Res.
, vol.48
, pp. 369-385
-
-
Bayless, K.J.1
Johnson, G.A.2
-
6
-
-
80052290593
-
Histone deacetylases: Anti-angiogenic targets in cancer therapy
-
Mottet, D.; Castronovo, V. Histone deacetylases: Anti-angiogenic targets in cancer therapy. Curr. Cancer Drug Targets 2010, 10, 898-913.
-
(2010)
Curr. Cancer Drug Targets
, vol.10
, pp. 898-913
-
-
Mottet, D.1
Castronovo, V.2
-
7
-
-
84866000222
-
Newly discovered angiogenesis inhibitors and their mechanisms of action
-
Miao, Z.H.; Feng, J.M.; Ding, J. Newly discovered angiogenesis inhibitors and their mechanisms of action. Acta Pharmacol. Sin. 2012, 33, 1103-1111.
-
(2012)
Acta Pharmacol. Sin.
, vol.33
, pp. 1103-1111
-
-
Miao, Z.H.1
Feng, J.M.2
Ding, J.3
-
8
-
-
77953685524
-
The odyssey of marine pharmaceuticals: A current pipeline perspective
-
Mayer, A.M.S.; Glaser, K.B.; Cuevas, C.; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; Newman, D.J.; Potts, B.C.; Shuster, D.E. The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol. Sci. 2010, 31, 255-265.
-
(2010)
Trends Pharmacol. Sci.
, vol.31
, pp. 255-265
-
-
Mayer, A.M.S.1
Glaser, K.B.2
Cuevas, C.3
Jacobs, R.S.4
Kem, W.5
Little, R.D.6
McIntosh, J.M.7
Newman, D.J.8
Potts, B.C.9
Shuster, D.E.10
-
9
-
-
84868261155
-
Current status on marine products with reversal effect on cancer multidrug resistance
-
Abraham, I.; El Sayed, K.; Chen, Z.S.; Guo, H. Current status on marine products with reversal effect on cancer multidrug resistance. Mar. Drugs 2012, 10, 2312-2321.
-
(2012)
Mar. Drugs
, vol.10
, pp. 2312-2321
-
-
Abraham, I.1
El Sayed, K.2
Chen, Z.S.3
Guo, H.4
-
10
-
-
65249123159
-
Antivascular actions of microtubule-binding drugs
-
Schwartz, E.L. Antivascular actions of microtubule-binding drugs. Clin. Cancer Res. 2009, 15, 2594-2601.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 2594-2601
-
-
Schwartz, E.L.1
-
11
-
-
0033853789
-
Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin
-
Natsume, T.; Watanabe, J.; Tamaoki, S.; Fujio, N.; Miyasaka, K.; Kobayashi, M. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn. J. Cancer Res. 2000, 91, 737-747.
-
(2000)
Jpn. J. Cancer Res.
, vol.91
, pp. 737-747
-
-
Natsume, T.1
Watanabe, J.2
Tamaoki, S.3
Fujio, N.4
Miyasaka, K.5
Kobayashi, M.6
-
12
-
-
77951206196
-
Anti-microtubule "plinabulin" chemical probe KPU-244-B3 labeled both α- And β-tubulin
-
Yamazaki, Y.; Sumikura, M.; Hidaka, K.; Yasui, H.; Kiso, Y.; Yakushiji, F.; Hayashi, Y. Anti-microtubule "plinabulin" chemical probe KPU-244-B3 labeled both α- and β-tubulin. Bioorg. Med. Chem. 2010, 18, 3169-3174.
-
(2010)
Bioorg. Med. Chem.
, vol.18
, pp. 3169-3174
-
-
Yamazaki, Y.1
Sumikura, M.2
Hidaka, K.3
Yasui, H.4
Kiso, Y.5
Yakushiji, F.6
Hayashi, Y.7
-
13
-
-
0029133540
-
The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain
-
Bai, R.; Taylor, G.F.; Cichacz, Z.A.; Herald, C.L.; Kepler, J.A.; Pettit, G.R.; Hamel, E. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. Biochemistry 1995, 34, 9714-9721.
-
(1995)
Biochemistry
, vol.34
, pp. 9714-9721
-
-
Bai, R.1
Taylor, G.F.2
Cichacz, Z.A.3
Herald, C.L.4
Kepler, J.A.5
Pettit, G.R.6
Hamel, E.7
-
14
-
-
0033083045
-
And isolaulimalide, new paclitaxel-like microtubule stabilizing agents
-
Mooberry, S.L.; Tien, G.; Hernandez, A.H.; Plubrukarn, A.; Davidson, B.S. Laulimalide and isolaulimalide, new paclitaxel-like microtubule stabilizing agents. Cancer Res. 1999, 59, 653-660.
-
(1999)
Cancer Res.
, vol.59
, pp. 653-660
-
-
Mooberry, S.L.1
Tien, G.2
Hernandez, A.H.3
Plubrukarn, A.4
Laulimalide, S.D.B.5
-
15
-
-
77955453358
-
Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping
-
Bennett, M.J.; Barakat, K.; Huzil, J.T.; Tuszynski, J.; Schriemer, D.C. Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem. Biol. 2010, 17, 725-734.
-
(2010)
Chem. Biol.
, vol.17
, pp. 725-734
-
-
Bennett, M.J.1
Barakat, K.2
Huzil, J.T.3
Tuszynski, J.4
Schriemer, D.C.5
-
16
-
-
0033760668
-
Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent
-
Watanabe, J.; Natsume, T.; Fujio, N.; Miyasaka, K.; Kobayashi, M. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 2000, 5, 345-353.
-
(2000)
Apoptosis
, vol.5
, pp. 345-353
-
-
Watanabe, J.1
Natsume, T.2
Fujio, N.3
Miyasaka, K.4
Kobayashi, M.5
-
17
-
-
84869206886
-
Unusual expression of red, fluorescence at M phase induced by anti-microtubule agents in He La cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci)
-
Honda-Uezono, A.; Kaida, A.; Michi, Y.; Harada, K.; Hayashi, Y.; Hayashi, Y.; Miura, M. Unusual expression of red, fluorescence at M phase induced by anti-microtubule agents in He La cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci). Biochem. Biophys. Res. Commun. 2012, 428, 224-229.
-
(2012)
Biochem. Biophys. Res. Commun.
, vol.428
, pp. 224-229
-
-
Honda-Uezono, A.1
Kaida, A.2
Michi, Y.3
Harada, K.4
Hayashi, Y.5
Hayashi, Y.6
Miura, M.7
-
18
-
-
77955488063
-
The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis
-
Rothmeier, A.S.; Schneiders, U.M.; Wiedmann, R.M.; Ischenko, I.; Bruns, C.J.; Rudy, A.; Zahler, S.; Vollmar, A.M. The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis. Int. J. Cancer 2010, 127, 1096-1105.
-
(2010)
Int. J. Cancer
, vol.127
, pp. 1096-1105
-
-
Rothmeier, A.S.1
Schneiders, U.M.2
Wiedmann, R.M.3
Ischenko, I.4
Bruns, C.J.5
Rudy, A.6
Zahler, S.7
Vollmar, A.M.8
-
19
-
-
84865345198
-
Low-dose laulimalide represents a novel molecular probe for investigating microtubule organization
-
Bennett, M.J.; Chan, G.K.; Rattner, J.B.; Schriemer, D.C. Low-dose laulimalide represents a novel molecular probe for investigating microtubule organization. Cell Cycle 2012, 11, 3045-3054.
-
(2012)
Cell Cycle
, vol.11
, pp. 3045-3054
-
-
Bennett, M.J.1
Chan, G.K.2
Rattner, J.B.3
Schriemer, D.C.4
-
20
-
-
33646118484
-
NPI-2358 is a tubulin-depolymerizing agent: In vitro evidence for activity as a tumor vascular-disrupting agent
-
Nicholson, B.; Lloyd, G.K.; Miller, B.R.; Palladino, M.A.; Kiso, Y.; Hayashi, Y.; Neuteboom, S.T.C. NPI-2358 is a tubulin-depolymerizing agent: In vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006, 17, 25-31.
-
(2006)
Anticancer Drugs
, vol.17
, pp. 25-31
-
-
Nicholson, B.1
Lloyd, G.K.2
Miller, B.R.3
Palladino, M.A.4
Kiso, Y.5
Hayashi, Y.6
Neuteboom, S.T.C.7
-
21
-
-
65349154519
-
Investigation of the marine compound spongistatin 1 links the inhibition of PKC α translocation to nonmitotic effects of tubulin antagonism in angiogenesis
-
Rothmeier, A.S.; Ischenko, I.; Joore, J.; Garczarczyk, D.; Furst, R.; Bruns, C.J.; Vollmar, A.M.; Zahler, S. Investigation of the marine compound spongistatin 1 links the inhibition of PKC α translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J. 2009, 23, 1127-1137.
-
(2009)
FASEB J
, vol.23
, pp. 1127-1137
-
-
Rothmeier, A.S.1
Ischenko, I.2
Joore, J.3
Garczarczyk, D.4
Furst, R.5
Bruns, C.J.6
Vollmar, A.M.7
Zahler, S.8
-
22
-
-
33645103854
-
The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere)
-
Lu, H.Y.; Murtagh, J.; Schwartz, E.L. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol. Pharmacol. 2006, 69, 1207-1215.
-
(2006)
Mol. Pharmacol.
, vol.69
, pp. 1207-1215
-
-
Lu, H.Y.1
Murtagh, J.2
Schwartz, E.L.3
-
23
-
-
34047212221
-
Antiangiogenic activity of TZT-1027 (Soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells
-
Watanabe, J.; Endo, Y.; Shimada, N.; Natsume, T.; Sasaki, T.; Kobayashi, M. Antiangiogenic activity of TZT-1027 (Soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells. In Vivo 2007, 21, 297-304.
-
(2007)
Vivo
, vol.21
, pp. 297-304
-
-
Watanabe, J.1
Endo, Y.2
Shimada, N.3
Natsume, T.4
Sasaki, T.5
Kobayashi, M.6
-
24
-
-
0033857963
-
TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death
-
Otani, M.; Natsume, T.; Watanabe, J.; Kobayashi, M.; Murakoshi, M.; Mikami, T.; Nakayama, T. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn. J. Cancer Res. 2000, 91, 837-844.
-
(2000)
Jpn. J. Cancer Res.
, vol.91
, pp. 837-844
-
-
Otani, M.1
Natsume, T.2
Watanabe, J.3
Kobayashi, M.4
Murakoshi, M.5
Mikami, T.6
Nakayama, T.7
-
25
-
-
84864349509
-
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
-
Millward, M.; Mainwaring, P.; Mita, A.; Federico, K.; Lloyd, G.K.; Reddinger, N.; Nawrocki, S.; Mita, M.; Spear, M.A. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest. New Drugs 2012, 30, 1065-1073.
-
(2012)
Invest. New Drugs
, vol.30
, pp. 1065-1073
-
-
Millward, M.1
Mainwaring, P.2
Mita, A.3
Federico, K.4
Lloyd, G.K.5
Reddinger, N.6
Nawrocki, S.7
Mita, M.8
Spear, M.A.9
-
26
-
-
0033925380
-
Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth
-
Udagawa, T.; Yuan, J.; Panigrahy, D.; Chang, Y.H.; Shah, J.; D'Amato, R.J. Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. J. Pharmacol. Exp. Ther. 2000, 294, 421-427.
-
(2000)
J. Pharmacol. Exp. Ther.
, vol.294
, pp. 421-427
-
-
Udagawa, T.1
Yuan, J.2
Panigrahy, D.3
Chang, Y.H.4
Shah, J.5
D'Amato, R.J.6
-
27
-
-
0030005414
-
Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125(FAK)) in prostate carcinoma
-
Duncan, M.D.; Harmon, J.W.; Duncan, K.L.K. Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125(FAK)) in prostate carcinoma. J. Surg. Res. 1996, 63, 359-363.
-
(1996)
J. Surg. Res.
, vol.63
, pp. 359-363
-
-
Duncan, M.D.1
Harmon, J.W.2
Duncan, K.L.K.3
-
28
-
-
0142026611
-
Depolymerization of actin filament by cytochalasin e induces interleukin-8 production and up-regulates CD54 in the HeLa epithelial cell line
-
Ikewaki, N.; Yamada, A.; Inoko, H. Depolymerization of actin filament by cytochalasin E induces interleukin-8 production and up-regulates CD54 in the HeLa epithelial cell line. Microbiol. Immunol. 2003, 47, 775-783.
-
(2003)
Microbiol. Immunol.
, vol.47
, pp. 775-783
-
-
Ikewaki, N.1
Yamada, A.2
Inoko, H.3
-
29
-
-
0023856779
-
Cytochalasin e enhances the protein kinase C-dependent process of secretion
-
Cox, A.C. Cytochalasin E enhances the protein kinase C-dependent process of secretion. Biochem. Biophys. Res. Commun. 1988, 150, 745-751.
-
(1988)
Biochem. Biophys. Res. Commun.
, vol.150
, pp. 745-751
-
-
Cox, A.C.1
-
30
-
-
10744224916
-
The tumor invasion inhibitor dihydromotuporamine C activates RHO, remodels stress fibers and focal adhesions, and stimulates sodium-proton exchange
-
McHardy, L.M.; Sinotte, R.; Troussard, A.; Sheldon, C.; Church, J.; Williams, D.E.; Andersen, R.J.; Dedhar, S.; Roberge, M.; Roskelley, C.D. The tumor invasion inhibitor dihydromotuporamine C activates RHO, remodels stress fibers and focal adhesions, and stimulates sodium-proton exchange. Cancer Res. 2004, 64, 1468-1474.
-
(2004)
Cancer Res
, vol.64
, pp. 1468-1474
-
-
McHardy, L.M.1
Sinotte, R.2
Troussard, A.3
Sheldon, C.4
Church, J.5
Williams, D.E.6
Andersen, R.J.7
Dedhar, S.8
Roberge, M.9
Roskelley, C.D.10
-
31
-
-
0035884377
-
Inhibition of tumor cell invasion and angiogenesis by motuporamines
-
Roskelley, C.D.; Williams, D.E.; McHardy, L.M.; Leong, K.G.; Troussard, A.; Karsan, A.; Andersen, R.J.; Dedhar, S.; Roberge, M. Inhibition of tumor cell invasion and angiogenesis by motuporamines. Cancer Res. 2001, 61, 6788-6794.
-
(2001)
Cancer Res
, vol.61
, pp. 6788-6794
-
-
Roskelley, C.D.1
Williams, D.E.2
McHardy, L.M.3
Leong, K.G.4
Troussard, A.5
Karsan, A.6
Andersen, R.J.7
Dedhar, S.8
Roberge, M.9
-
32
-
-
84858685501
-
Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed
-
Gryder, B.E.; Sodji, Q.H.; Oyelere, A.K. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med. Chem. 2012, 4, 505-524.
-
(2012)
Future Med. Chem.
, vol.4
, pp. 505-524
-
-
Gryder, B.E.1
Sodji, Q.H.2
Oyelere, A.K.3
-
33
-
-
78649330519
-
The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: Cytotoxic drug and inducer of sodium-iodide symporter (NIS)
-
Fortunati, N.; Catalano, M.G.; Marano, F.; Mugoni, V.; Pugliese, M.; Bosco, O.; Mainini, F.; Boccuzzi, G. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: Cytotoxic drug and inducer of sodium-iodide symporter (NIS). Breast Cancer Res. Treat. 2010, 124, 667-675.
-
(2010)
Breast Cancer Res. Treat.
, vol.124
, pp. 667-675
-
-
Fortunati, N.1
Catalano, M.G.2
Marano, F.3
Mugoni, V.4
Pugliese, M.5
Bosco, O.6
Mainini, F.7
Boccuzzi, G.8
-
34
-
-
31544464120
-
Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589
-
Qian, D.Z.; Kato, Y.; Shabbeer, S.; Wei, Y.F.; Verheul, H.M.W.; Salumbides, B.; Sanni, T.; Atadja, P.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589. Clin. Cancer Res. 2006, 12, 634-642.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 634-642
-
-
Qian, D.Z.1
Kato, Y.2
Shabbeer, S.3
Wei, Y.F.4
Verheul, H.M.W.5
Salumbides, B.6
Sanni, T.7
Atadja, P.8
Pili, R.9
-
35
-
-
33845199114
-
Azumamides A-E: Histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis
-
Nakao, Y.; Yoshida, S.; Matsunaga, S.; Shindoh, N.; Terada, Y.; Nagai, K.; Yamashita, J.K.; Ganesan, A.; van Soest, R.W.; Fusetani, N. Azumamides A-E: Histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis. Angew. Chem. Int. Ed. Engl. 2006, 45, 7553-7557.
-
(2006)
Angew. Chem. Int. Ed. Engl.
, vol.45
, pp. 7553-7557
-
-
Nakao, Y.1
Yoshida, S.2
Matsunaga, S.3
Shindoh, N.4
Terada, Y.5
Nagai, K.6
Yamashita, J.K.7
Ganesan, A.8
Van Soest, R.W.9
Fusetani, N.10
-
36
-
-
42949139951
-
Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells
-
Nakao, Y.; Narazaki, G.; Hoshino, T.; Maeda, S.; Yoshida, M.; Maejima, H.; Yamashita, J.K. Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg. Med. Chem. Lett. 2008, 18, 2982-2984.
-
(2008)
Bioorg. Med. Chem. Lett.
, vol.18
, pp. 2982-2984
-
-
Nakao, Y.1
Narazaki, G.2
Hoshino, T.3
Maeda, S.4
Yoshida, M.5
Maejima, H.6
Yamashita, J.K.7
-
37
-
-
0038627550
-
Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase
-
Pina, I.C.; Gautschi, J.T.; Wang, G.Y.S.; Sanders, M.L.; Schmitz, F.J.; France, D.; Cornell-Kennon, S.; Sambucetti, L.C.; Remiszewski, S.W.; Perez, L.B.; et al. Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 2003, 68, 3866-3873.
-
(2003)
J. Org. Chem.
, vol.68
, pp. 3866-3873
-
-
Pina, I.C.1
Gautschi, J.T.2
Wang, G.Y.S.3
Sanders, M.L.4
Schmitz, F.J.5
France, D.6
Cornell-Kennon, S.7
Sambucetti, L.C.8
Remiszewski, S.W.9
Perez, L.B.10
-
38
-
-
0346094302
-
Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro
-
Shim, J.S.; Lee, H.S.; Shin, J.; Kwon, H.J. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett. 2004, 203, 163-169.
-
(2004)
Cancer Lett
, vol.203
, pp. 163-169
-
-
Shim, J.S.1
Lee, H.S.2
Shin, J.3
Kwon, H.J.4
-
39
-
-
37349061341
-
A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells
-
Ahn, M.Y.; Jung, J.H.; Na, Y.J.; Kim, H.S. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol. Oncol. 2008, 108, 27-33.
-
(2008)
Gynecol. Oncol.
, vol.108
, pp. 27-33
-
-
Ahn, M.Y.1
Jung, J.H.2
Na, Y.J.3
Kim, H.S.4
-
40
-
-
33847657556
-
Psammaplin A is a natural prodrug that inhibits class i histone deacetylase
-
Kim, D.H.; Shin, J.; Kwon, H.J. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp. Mol. Med. 2007, 39, 47-55.
-
(2007)
Exp. Mol. Med.
, vol.39
, pp. 47-55
-
-
Kim, D.H.1
Shin, J.2
Kwon, H.J.3
-
41
-
-
79955047006
-
Methionine aminopeptidases as potential targets for treatment of gastrointestinal cancers and other tumors
-
Mauriz, J.L.; Martin-Renedo, J.; Garcia-Palomo, A.; Tunon, M.J.; Gonzalez-Gallego, J. Methionine aminopeptidases as potential targets for treatment of gastrointestinal cancers and other tumors. Curr. Drug Targets 2010, 11, 1430-1448.
-
(2010)
Curr. Drug Targets
, vol.11
, pp. 1430-1448
-
-
Mauriz, J.L.1
Martin-Renedo, J.2
Garcia-Palomo, A.3
Tunon, M.J.4
Gonzalez-Gallego, J.5
-
42
-
-
70349290496
-
Roles of P67/MetAP2 as a tumor suppressor
-
Datta, B. Roles of P67/MetAP2 as a tumor suppressor. Biochim. Biophys. Acta 2009, 1796, 281-292.
-
(2009)
Biochim. Biophys. Acta
, vol.1796
, pp. 281-292
-
-
Datta, B.1
-
43
-
-
16644386079
-
Role of aminopeptidase in angiogenesis
-
Sato, Y. Role of aminopeptidase in angiogenesis. Biol. Pharm. Bull. 2004, 27, 772-776.
-
(2004)
Biol. Pharm. Bull.
, vol.27
, pp. 772-776
-
-
Sato, Y.1
-
44
-
-
77956245266
-
Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides
-
Hines, J.; Ju, R.; Dutschman, G.E.; Cheng, Y.C.; Crews, C.M. Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides. J. Pharmacol. Exp. Ther. 2010, 334, 729-738.
-
(2010)
J. Pharmacol. Exp. Ther.
, vol.334
, pp. 729-738
-
-
Hines, J.1
Ju, R.2
Dutschman, G.E.3
Cheng, Y.C.4
Crews, C.M.5
-
45
-
-
34547807609
-
FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470)
-
Chen, G.J.; Weylie, B.; Hu, C.; Zhu, J.; Forough, R. FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470). J. Cell. Biochem. 2007, 101, 1492-1504.
-
(2007)
J. Cell. Biochem.
, vol.101
, pp. 1492-1504
-
-
Chen, G.J.1
Weylie, B.2
Hu, C.3
Zhu, J.4
Forough, R.5
-
46
-
-
84866863979
-
Structural analysis of bengamide derivatives as inhibitors of methionine aminopeptidases
-
Xu, W.; Lu, J.P.; Ye, Q.Z. Structural analysis of bengamide derivatives as inhibitors of methionine aminopeptidases. J. Med. Chem. 2012, 55, 8021-8027.
-
(2012)
J. Med. Chem.
, vol.55
, pp. 8021-8027
-
-
Xu, W.1
Lu, J.P.2
Ye, Q.Z.3
-
47
-
-
0035950061
-
Synthesis and antitumor activity of ester-modified analogues of bengamide B
-
Kinder, F.R.; Versace, R.W.; Bair, K.W.; Bontempo, J.M.; Cesarz, D.; Chen, S.; Crews, P.; Czuchta, A.M.; Jagoe, C.T.; Mou, Y.; et al. Synthesis and antitumor activity of ester-modified analogues of bengamide B. J. Med. Chem. 2001, 44, 3692-3699.
-
(2001)
J. Med. Chem.
, vol.44
, pp. 3692-3699
-
-
Kinder, F.R.1
Versace, R.W.2
Bair, K.W.3
Bontempo, J.M.4
Cesarz, D.5
Chen, S.6
Crews, P.7
Czuchta, A.M.8
Jagoe, C.T.9
Mou, Y.10
-
48
-
-
9144222006
-
Proteomics-based target identification: Bengamides as a new class of methionine aminopeptidase inhibitors
-
Towbin, H.; Bair, K.W.; DeCaprio, J.A.; Eck, M.J.; Kim, S.; Kinder, F.R.; Morollo, A.; Mueller, D.R.; Schindler, P.; Song, H.K.; et al. Proteomics-based target identification: Bengamides as a new class of methionine aminopeptidase inhibitors. J. Biol. Chem. 2003, 278, 52964-52971.
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 52964-52971
-
-
Towbin, H.1
Bair, K.W.2
Decaprio, J.A.3
Eck, M.J.4
Kim, S.5
Kinder, F.R.6
Morollo, A.7
Mueller, D.R.8
Schindler, P.9
Song, H.K.10
-
49
-
-
33845715488
-
A phase i and pharmacokinetic study of LAF389 administered to patients with advanced cancer
-
Dumez, H.; Gall, H.; Capdeville, R.; Dutreix, C.; van Oosterom, A.T.; Giaccone, G. A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anticancer Drugs 2007, 18, 219-225.
-
(2007)
Anticancer Drugs
, vol.18
, pp. 219-225
-
-
Dumez, H.1
Gall, H.2
Capdeville, R.3
Dutreix, C.4
Van Oosterom, A.T.5
Giaccone, G.6
-
50
-
-
1942484776
-
Study of puupehenone and related compounds as inhibitors of angiogenesis
-
Castro, M.E.; Gonzalez-Iriarte, M.; Barrero, A.F.; Salvador-Tormo, N.; Munoz-Chapuli, R.; Medina, M.A.; Quesada, A.R. Study of puupehenone and related compounds as inhibitors of angiogenesis. Int. J. Cancer 2004, 110, 31-38.
-
(2004)
Int. J. Cancer
, vol.110
, pp. 31-38
-
-
Castro, M.E.1
Gonzalez-Iriarte, M.2
Barrero, A.F.3
Salvador-Tormo, N.4
Munoz-Chapuli, R.5
Medina, M.A.6
Quesada, A.R.7
-
51
-
-
38449087673
-
Streptochlorin, a marine natural product, inhibits NF-κB activation and suppresses angiogenesis in vitro
-
Choi, I.K.; Shin, H.J.; Lee, H.S.; Kwon, H.J. Streptochlorin, a marine natural product, inhibits NF-κB activation and suppresses angiogenesis in vitro. J. Microbiol. Biotechnol. 2007, 17, 1338-1343.
-
(2007)
J. Microbiol. Biotechnol.
, vol.17
, pp. 1338-1343
-
-
Choi, I.K.1
Shin, H.J.2
Lee, H.S.3
Kwon, H.J.4
-
52
-
-
40649123558
-
The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8
-
Wrasidlo, W.; Mielgo, A.; Torres, V.A.; Barbero, S.; Stoletov, K.; Suyama, T.L.; Klemke, R.L.; Gerwick, W.H.; Carson, D.A.; Stupack, D.G. The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc. Natl. Acad. Sci. USA 2008, 105, 2313-2318.
-
(2008)
Proc. Natl. Acad. Sci. USA
, vol.105
, pp. 2313-2318
-
-
Wrasidlo, W.1
Mielgo, A.2
Torres, V.A.3
Barbero, S.4
Stoletov, K.5
Suyama, T.L.6
Klemke, R.L.7
Gerwick, W.H.8
Carson, D.A.9
Stupack, D.G.10
-
53
-
-
33646085774
-
Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells
-
Aoki, S.; Cho, S.; Ono, M.; Kuwano, T.; Nakao, S.; Kuwano, M.; Nakagawa, S.; Gao, J.Q.; Mayumi, T.; Shibuya, M.; et al. Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs 2006, 17, 269-278.
-
(2006)
Anticancer Drugs
, vol.17
, pp. 269-278
-
-
Aoki, S.1
Cho, S.2
Ono, M.3
Kuwano, T.4
Nakao, S.5
Kuwano, M.6
Nakagawa, S.7
Gao, J.Q.8
Mayumi, T.9
Shibuya, M.10
-
54
-
-
67650759754
-
Pyripyropenes, fungal sesquiterpenes conjugated with α-pyrone and pyridine moieties, exhibits anti-angiogenic activity against human umbilical vein endothelial cells
-
Hayashi, A.; Arai, M.; Fujita, M.; Kobayashi, M. Pyripyropenes, fungal sesquiterpenes conjugated with α-pyrone and pyridine moieties, exhibits anti-angiogenic activity against human umbilical vein endothelial cells. Biol. Pharm. Bull. 2009, 32, 1261-1265.
-
(2009)
Biol. Pharm. Bull.
, vol.32
, pp. 1261-1265
-
-
Hayashi, A.1
Arai, M.2
Fujita, M.3
Kobayashi, M.4
-
55
-
-
34249676335
-
Novel isomarabarican triterpenes, exhibiting selective anti-proliferative activity against vascular endothelial cells, from marine sponge Rhabdastrella globostellata
-
Aoki, S.; Sanagawa, M.; Watanabe, Y.; Setiawan, A.; Arai, M.; Kobayashi, M. Novel isomarabarican triterpenes, exhibiting selective anti-proliferative activity against vascular endothelial cells, from marine sponge Rhabdastrella globostellata. Bioorg. Med. Chem. 2007, 15, 4818-4828.
-
(2007)
Bioorg. Med. Chem.
, vol.15
, pp. 4818-4828
-
-
Aoki, S.1
Sanagawa, M.2
Watanabe, Y.3
Setiawan, A.4
Arai, M.5
Kobayashi, M.6
-
56
-
-
51049123588
-
Streptopyrrolidine, an angiogenesis inhibitor from a marine-derived Streptomyces sp. KORDI-3973
-
Shin, H.J.; Kim, T.S.; Lee, H.S.; Park, J.Y.; Choi, I.K.; Kwon, H.J. Streptopyrrolidine, an angiogenesis inhibitor from a marine-derived Streptomyces sp. KORDI-3973. Phytochemistry 2008, 69, 2363-2366.
-
(2008)
Phytochemistry
, vol.69
, pp. 2363-2366
-
-
Shin, H.J.1
Kim, T.S.2
Lee, H.S.3
Park, J.Y.4
Choi, I.K.5
Kwon, H.J.6
-
57
-
-
37249084197
-
A polysaccharide isolated from the brown seaweed Sargassum stenophyllum exerts antivasculogenic effects evidenced by modified morphogenesis
-
Dias, P.F.; Siqueira, J.M., Jr.; Maraschin, M.; Ferreira, A.G.; Gagliardi, A.R.; Ribeiro-do-Valle, R.M. A polysaccharide isolated from the brown seaweed Sargassum stenophyllum exerts antivasculogenic effects evidenced by modified morphogenesis. Microvasc. Res. 2008, 75, 34-44.
-
(2008)
Microvasc. Res.
, vol.75
, pp. 34-44
-
-
Dias, P.F.1
Siqueira Jr., J.M.2
Maraschin, M.3
Ferreira, A.G.4
Gagliardi, A.R.5
Ribeiro-Do-Valle, R.M.6
-
58
-
-
0242416638
-
Antiangiogenic properties of a sulfated galactan isolated from a marine green alga, Codium cylindricum
-
Matsubara, K.; Mori, M.; Matsumoto, H.; Hori, K.; Miyazawa, K. Antiangiogenic properties of a sulfated galactan isolated from a marine green alga, Codium cylindricum. J. Appl. Phycol. 2003, 15, 87-90.
-
(2003)
J. Appl. Phycol.
, vol.15
, pp. 87-90
-
-
Matsubara, K.1
Mori, M.2
Matsumoto, H.3
Hori, K.4
Miyazawa, K.5
-
59
-
-
84861818270
-
Fucoidan extract derived from Undaria pinnatifida inhibits angiogenesis by human umbilical vein endothelial cells
-
Liu, F.; Wang, J.; Chang, A.K.; Liu, B.; Yang, L.L.; Li, Q.M.; Wang, P.S.; Zou, X.Y. Fucoidan extract derived from Undaria pinnatifida inhibits angiogenesis by human umbilical vein endothelial cells. Phytomedicine 2012, 19, 797-803.
-
(2012)
Phytomedicine
, vol.19
, pp. 797-803
-
-
Liu, F.1
Wang, J.2
Chang, A.K.3
Liu, B.4
Yang, L.L.5
Li, Q.M.6
Wang, P.S.7
Zou, X.Y.8
-
60
-
-
84865175152
-
Anticancer properties and mechanisms of fucoidan on mouse breast cancer in vitro and in vivo
-
Xue, M.; Ge, Y.; Zhang, J.; Wang, Q.; Hou, L.; Liu, Y.; Sun, L.; Li, Q. Anticancer properties and mechanisms of fucoidan on mouse breast cancer in vitro and in vivo. PLoS One 2012, 7, e43483.
-
(2012)
PLoS One
, vol.7
-
-
Xue, M.1
Ge, Y.2
Zhang, J.3
Wang, Q.4
Hou, L.5
Liu, Y.6
Sun, L.7
Li, Q.8
-
61
-
-
37049013563
-
Total synthesis and absolute configuration of laurenditerpenol: A hypoxia inducible factor-1 activation inhibitor
-
Chittiboyina, A.G.; Kumar, G.M.; Carvalho, P.B.; Liu, Y.; Zhou, Y.D.; Nagle, D.G.; Avery, M.A. Total synthesis and absolute configuration of laurenditerpenol: A hypoxia inducible factor-1 activation inhibitor. J. Med. Chem. 2007, 50, 6299-6302.
-
(2007)
J. Med. Chem.
, vol.50
, pp. 6299-6302
-
-
Chittiboyina, A.G.1
Kumar, G.M.2
Carvalho, P.B.3
Liu, Y.4
Zhou, Y.D.5
Nagle, D.G.6
Avery, M.A.7
-
62
-
-
70349564965
-
Synthesis of neolamellarin A, an inhibitor of hypoxia-inducible factor-1
-
Arafeh, K.M.; Ullah, N. Synthesis of neolamellarin A, an inhibitor of hypoxia-inducible factor-1. Nat. Prod. Commun. 2009, 4, 925-926.
-
(2009)
Nat. Prod. Commun.
, vol.4
, pp. 925-926
-
-
Arafeh, K.M.1
Ullah, N.2
-
63
-
-
3042743711
-
Antiangiogenic activity of aplidine, a new agent of marine origin
-
Taraboletti, G.; Poli, M.; Dossi, R.; Manenti, L.; Borsotti, P.; Faircloth, G.T.; Broggini, M.; D'Incalci, M.; Ribatti, D.; Giavazzi, R. Antiangiogenic activity of aplidine, a new agent of marine origin. Br. J. Cancer 2004, 90, 2418-2424.
-
(2004)
Br. J. Cancer
, vol.90
, pp. 2418-2424
-
-
Taraboletti, G.1
Poli, M.2
Dossi, R.3
Manenti, L.4
Borsotti, P.5
Faircloth, G.T.6
Broggini, M.7
D'Incalci, M.8
Ribatti, D.9
Giavazzi, R.10
-
64
-
-
28244433861
-
Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes
-
Straight, A.M.; Oakley, K.; Moores, R.; Bauer, A.J.; Patel, A.; Tuttle, R.M.; Jimeno, J.; Francis, G.L. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother. Pharmacol. 2006, 57, 7-14.
-
(2006)
Cancer Chemother. Pharmacol.
, vol.57
, pp. 7-14
-
-
Straight, A.M.1
Oakley, K.2
Moores, R.3
Bauer, A.J.4
Patel, A.5
Tuttle, R.M.6
Jimeno, J.7
Francis, G.L.8
-
65
-
-
44949219133
-
Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma
-
Caers, J.; Menu, E.; de Raeve, H.; Lepage, D.; van Valckenborgh, E.; van Camp, B.; Alvarez, E.; Vanderkerken, K. Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br. J. Cancer 2008, 98, 1966-1974.
-
(2008)
Br. J. Cancer
, vol.98
, pp. 1966-1974
-
-
Caers, J.1
Menu, E.2
De Raeve, H.3
Lepage, D.4
Van Valckenborgh, E.5
Van Camp, B.6
Alvarez, E.7
Vanderkerken, K.8
-
66
-
-
15644374381
-
Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature
-
Sills, A.K.; Williams, J.I.; Tyler, B.M.; Epstein, D.S.; Sipos, E.P.; Davis, J.D.; McLane, M.P.; Pitchford, S.; Cheshire, K.; Cannon, F.H.; et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. 1998, 58, 2784-2792.
-
(1998)
Cancer Res.
, vol.58
, pp. 2784-2792
-
-
Sills, A.K.1
Williams, J.I.2
Tyler, B.M.3
Epstein, D.S.4
Sipos, E.P.5
Davis, J.D.6
McLane, M.P.7
Pitchford, S.8
Cheshire, K.9
Cannon, F.H.10
-
67
-
-
0347991936
-
Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat
-
Ciulla, T.A.; Criswell, M.H.; Danis, R.P.; Williams, J.I.; McLane, M.P.; Holroyd, K.J. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 2003, 23, 808-814.
-
(2003)
Retina
, vol.23
, pp. 808-814
-
-
Ciulla, T.A.1
Criswell, M.H.2
Danis, R.P.3
Williams, J.I.4
McLane, M.P.5
Holroyd, K.J.6
-
68
-
-
12444278903
-
A phase i and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor
-
Hao, D.; Hammond, L.A.; Eckhardt, S.G.; Patnaik, A.; Takimoto, C.H.; Schwartz, G.H.; Goetz, A.D.; Tolcher, A.W.; McCreery, H.A.; Mamun, K.; et al. A phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. Clin. Cancer Res. 2003, 9, 2465-2471.
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 2465-2471
-
-
Hao, D.1
Hammond, L.A.2
Eckhardt, S.G.3
Patnaik, A.4
Takimoto, C.H.5
Schwartz, G.H.6
Goetz, A.D.7
Tolcher, A.W.8
McCreery, H.A.9
Mamun, K.10
-
69
-
-
84874520061
-
Squalamine and its derivatives as potential antitubercular compounds
-
Walker, B.T.; Houston, T.A. Squalamine and its derivatives as potential antitubercular compounds. Tuberculosis 2012, 93, 102-103.
-
(2012)
Tuberculosis
, vol.93
, pp. 102-103
-
-
Walker, B.T.1
Houston, T.A.2
-
70
-
-
84866602844
-
Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia
-
Hraiech, S.; Bregeon, F.; Brunel, J.M.; Rolain, J.M.; Lepidi, H.; Andrieu, V.; Raoult, D.; Papazian, L.; Roch, A. Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia. J. Antimicrob. Chemother. 2012, 67, 2452-2458.
-
(2012)
J. Antimicrob. Chemother.
, vol.67
, pp. 2452-2458
-
-
Hraiech, S.1
Bregeon, F.2
Brunel, J.M.3
Rolain, J.M.4
Lepidi, H.5
Andrieu, V.6
Raoult, D.7
Papazian, L.8
Roch, A.9
-
71
-
-
0037455147
-
Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora
-
Feling, R.H.; Buchanan, G.O.; Mincer, T.J.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew. Chem. Int. Ed. Engl. 2003, 42, 355-357.
-
(2003)
Angew. Chem. Int. Ed. Engl.
, vol.42
, pp. 355-357
-
-
Feling, R.H.1
Buchanan, G.O.2
Mincer, T.J.3
Kauffman, C.A.4
Jensen, P.R.5
Fenical, W.6
-
72
-
-
27644562277
-
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
-
Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8, 407-419.
-
(2005)
Cancer Cell
, vol.8
, pp. 407-419
-
-
Chauhan, D.1
Catley, L.2
Li, G.3
Podar, K.4
Hideshima, T.5
Velankar, M.6
Mitsiades, C.7
Mitsiades, N.8
Yasui, H.9
Letai, A.10
-
73
-
-
34948881265
-
NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB-regulated gene products
-
Ahn, K.S.; Sethi, G.; Chao, T.H.; Neuteboom, S.T.C.; Chaturvedi, M.M.; Palladino, M.A.; Younes, A.; Aggarwal, B.B. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB-regulated gene products. Blood 2007, 110, 2286-2295.
-
(2007)
Blood
, vol.110
, pp. 2286-2295
-
-
Ahn, K.S.1
Sethi, G.2
Chao, T.H.3
Neuteboom, S.T.C.4
Chaturvedi, M.M.5
Palladino, M.A.6
Younes, A.7
Aggarwal, B.B.8
Salinosporamide, A.9
-
74
-
-
62449203027
-
Control of HIF-1α expression by eIF2α phosphorylation- mediated translational repression
-
Zhu, K.Y.; Chan, W.; Heymach, J.; Wilkinson, M.; McConkey, D.J. Control of HIF-1α expression by eIF2α phosphorylation-mediated translational repression. Cancer Res. 2009, 69, 1836-1843.
-
(2009)
Cancer Res
, vol.69
, pp. 1836-1843
-
-
Zhu, K.Y.1
Chan, W.2
Heymach, J.3
Wilkinson, M.4
McConkey, D.J.5
-
75
-
-
84860338528
-
Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ
-
Irie, K.; Yanagita, R.C.; Nakagawa, Y. Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ. Med. Res. Rev. 2012, 32, 518-535.
-
(2012)
Med. Res. Rev.
, vol.32
, pp. 518-535
-
-
Irie, K.1
Yanagita, R.C.2
Nakagawa, Y.3
-
76
-
-
0028167842
-
Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes
-
Kazanietz, M.G.; Lewin, N.E.; Gao, F.; Pettit, G.R.; Blumberg, P.M. Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Mol. Pharmacol. 1994, 46, 374-379.
-
(1994)
Mol. Pharmacol.
, vol.46
, pp. 374-379
-
-
Kazanietz, M.G.1
Lewin, N.E.2
Gao, F.3
Pettit, G.R.4
Blumberg, P.M.5
-
77
-
-
0028126624
-
Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation
-
Szallasi, Z.; Denning, M.F.; Smith, C.B.; Dlugosz, A.A.; Yuspa, S.H.; Pettit, G.R.; Blumberg, P.M. Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Mol. Pharmacol. 1994, 46, 840-850.
-
(1994)
Mol. Pharmacol.
, vol.46
, pp. 840-850
-
-
Szallasi, Z.1
Denning, M.F.2
Smith, C.B.3
Dlugosz, A.A.4
Yuspa, S.H.5
Pettit, G.R.6
Blumberg, P.M.7
-
78
-
-
0028055160
-
Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts
-
Szallasi, Z.; Smith, C.B.; Pettit, G.R.; Blumberg, P.M. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J. Biol. Chem. 1994, 269, 2118-2124.
-
(1994)
J. Biol. Chem.
, vol.269
, pp. 2118-2124
-
-
Szallasi, Z.1
Smith, C.B.2
Pettit, G.R.3
Blumberg, P.M.4
-
79
-
-
1842582465
-
Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: A New York Gynecologic Oncology Group study
-
Nezhat, F.; Wadler, S.; Muggia, F.; Mandeli, J.; Goldberg, G.; Rahaman, J.; Runowicz, C.; Murgo, A.J.; Gardner, G.J. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: A New York Gynecologic Oncology Group study. Gynecol. Oncol. 2004, 93, 144-148.
-
(2004)
Gynecol. Oncol.
, vol.93
, pp. 144-148
-
-
Nezhat, F.1
Wadler, S.2
Muggia, F.3
Mandeli, J.4
Goldberg, G.5
Rahaman, J.6
Runowicz, C.7
Murgo, A.J.8
Gardner, G.J.9
-
80
-
-
34250902930
-
Targeting the protein kinase C family: Are we there yet?
-
Mackay, H.J.; Twelves, C.J. Targeting the protein kinase C family: Are we there yet? Nat. Rev. Cancer 2007, 7, 554-562.
-
(2007)
Nat. Rev. Cancer
, vol.7
, pp. 554-562
-
-
Mackay, H.J.1
Twelves, C.J.2
-
81
-
-
84865057198
-
FASCAPLYSIN as a specific inhibitor for CDK4: Insights from molecular modelling
-
Shafiq, M.I.; Steinbrecher, T.; Schmid, R. FASCAPLYSIN as a specific inhibitor for CDK4: Insights from molecular modelling. PLoS One 2012, 7, e42612.
-
(2012)
PLoS One
, vol.7
-
-
Shafiq, M.I.1
Steinbrecher, T.2
Schmid, R.3
-
82
-
-
77956878953
-
Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity
-
Zheng, Y.L.; Lu, X.L.; Lin, J.; Chen, H.M.; Yan, X.J.; Wang, F.; Xu, W.F. Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity. Biomed. Pharmacother. 2010, 64, 527-533.
-
(2010)
Biomed. Pharmacother.
, vol.64
, pp. 527-533
-
-
Zheng, Y.L.1
Lu, X.L.2
Lin, J.3
Chen, H.M.4
Yan, X.J.5
Wang, F.6
Xu, W.F.7
-
83
-
-
79959619770
-
Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model
-
Yan, X.J.; Chen, H.M.; Lu, X.L.; Wang, F.; Xu, W.F.; Jin, H.X.; Zhu, P. Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model. Eur. J. Pharm. Sci. 2011, 43, 251-259.
-
(2011)
Eur. J. Pharm. Sci.
, vol.43
, pp. 251-259
-
-
Yan, X.J.1
Chen, H.M.2
Lu, X.L.3
Wang, F.4
Xu, W.F.5
Jin, H.X.6
Zhu, P.7
-
84
-
-
33846269340
-
Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo
-
Lin, J.; Yan, X.J.; Chen, H.M. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo. Cancer Chemother. Pharmacol. 2007, 59, 439-445.
-
(2007)
Cancer Chemother. Pharmacol.
, vol.59
, pp. 439-445
-
-
Lin, J.1
Yan, X.J.2
Chen, H.M.3
-
85
-
-
33644946432
-
Cortistatins A, B, C, and D, anti-angiogenic steroidal alkaloids, from the marine sponge Corticium simplex
-
Aoki, S.; Watanabe, Y.; Sanagawa, M.; Setiawan, A.; Kotoku, N.; Kobayashi, M. Cortistatins A, B, C, and D, anti-angiogenic steroidal alkaloids, from the marine sponge Corticium simplex. J. Am. Chem. Soc. 2006, 128, 3148-3149.
-
(2006)
J. Am. Chem. Soc.
, vol.128
, pp. 3148-3149
-
-
Aoki, S.1
Watanabe, Y.2
Sanagawa, M.3
Setiawan, A.4
Kotoku, N.5
Kobayashi, M.6
-
86
-
-
34548528924
-
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids
-
Aoki, S.; Watanabe, Y.; Tanabe, D.; Arai, M.; Suna, H.; Miyamoto, K.; Tsujibo, H.; Tsujikawa, K.; Yamamoto, H.; Kobayashi, M. Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids. Bioorg. Med. Chem. 2007, 15, 6758-6762.
-
(2007)
Bioorg. Med. Chem.
, vol.15
, pp. 6758-6762
-
-
Aoki, S.1
Watanabe, Y.2
Tanabe, D.3
Arai, M.4
Suna, H.5
Miyamoto, K.6
Tsujibo, H.7
Tsujikawa, K.8
Yamamoto, H.9
Kobayashi, M.10
-
87
-
-
70449120427
-
Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11
-
Cee, V.J.; Chen, D.Y. K.; Lee, M.R.; Nicolaou, K.C. Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. Angew. Chem. Int. Ed. Engl. 2009, 48, 8952-8957.
-
(2009)
Angew. Chem. Int. Ed. Engl.
, vol.48
, pp. 8952-8957
-
-
Cee, V.J.1
Chen, D.Y.K.2
Lee, M.R.3
Nicolaou, K.C.4
-
88
-
-
0036211156
-
Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue
-
Dupont, E.; Falardeau, P.; Mousa, S.A.; Dimitriadou, V.; Pepin, M.C.; Wang, T.Q.; Alaoui-Jamali, M.A. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin. Exp. Metastas 2002, 19, 145-153.
-
(2002)
Clin. Exp. Metastas
, vol.19
, pp. 145-153
-
-
Dupont, E.1
Falardeau, P.2
Mousa, S.A.3
Dimitriadou, V.4
Pepin, M.C.5
Wang, T.Q.6
Alaoui-Jamali, M.A.7
-
89
-
-
0036554985
-
The antiangiogenic agent Neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects
-
Beliveau, R.; Gingras, D.; Kruger, E.A.; Lamy, S.; Sirois, P.; Tranqui, L.; Baffert, F.; Beaulieu, E.; Dimitriadou, V.; Pepin, M.C.; et al. The antiangiogenic agent Neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin. Cancer Res. 2002, 8, 1242-1250.
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 1242-1250
-
-
Beliveau, R.1
Gingras, D.2
Kruger, E.A.3
Lamy, S.4
Sirois, P.5
Tranqui, L.6
Baffert, F.7
Beaulieu, E.8
Dimitriadou, V.9
Pepin, M.C.10
-
90
-
-
0035060804
-
Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound
-
Gingras, D.; Renaud, A.; Mousseau, N.; Beaulieu, E.; Kachra, Z.; Beliveau, R. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res. 2001, 21, 145-155.
-
(2001)
Anticancer Res
, vol.21
, pp. 145-155
-
-
Gingras, D.1
Renaud, A.2
Mousseau, N.3
Beaulieu, E.4
Kachra, Z.5
Beliveau, R.6
-
91
-
-
1042279668
-
The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity
-
Gingras, D.; Labelle, D.; Nyalendo, C.; Boivin, D.; Demeule, M.; Barthomeuf, C.; Beliveau, R. The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity. Invest. New Drugs 2004, 22, 17-26.
-
(2004)
Invest. New Drugs
, vol.22
, pp. 17-26
-
-
Gingras, D.1
Labelle, D.2
Nyalendo, C.3
Boivin, D.4
Demeule, M.5
Barthomeuf, C.6
Beliveau, R.7
-
92
-
-
0036692153
-
The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis
-
Boivin, D.; Gendron, S.; Beaulieu, E.; Gingras, D.; Beliveau, R. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol. Cancer Ther. 2002, 1, 795-802.
-
(2002)
Mol. Cancer Ther.
, vol.1
, pp. 795-802
-
-
Boivin, D.1
Gendron, S.2
Beaulieu, E.3
Gingras, D.4
Beliveau, R.5
-
93
-
-
0035207897
-
Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials
-
Falardeau, P.; Champagne, P.; Poyet, P.; Hariton, C.; Dupont, E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol. 2001, 28, 620-625.
-
(2001)
Semin. Oncol.
, vol.28
, pp. 620-625
-
-
Falardeau, P.1
Champagne, P.2
Poyet, P.3
Hariton, C.4
Dupont, E.5
-
94
-
-
77953695968
-
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: A randomized phase III trial
-
Lu, C.; Lee, J.J.; Komaki, R.; Herbst, R.S.; Feng, L.; Evans, W.K.; Choy, H.; Desjardins, P.; Esparaz, B.T.; Truong, M.T.; et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: A randomized phase III trial. J. Natl. Cancer Inst. 2010, 102, 859-865.
-
(2010)
J. Natl. Cancer Inst.
, vol.102
, pp. 859-865
-
-
Lu, C.1
Lee, J.J.2
Komaki, R.3
Herbst, R.S.4
Feng, L.5
Evans, W.K.6
Choy, H.7
Desjardins, P.8
Esparaz, B.T.9
Truong, M.T.10
-
95
-
-
35148862970
-
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941
-
Escudier, B.; Choueiri, T.K.; Oudard, S.; Szczylik, C.; Negrier, S.; Ravaud, A.; Chevreau, C.; Venner, P.; Champagne, P.; Croteau, D.; et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941. J. Urol. 2007, 178, 1901-1905.
-
(2007)
J. Urol.
, vol.178
, pp. 1901-1905
-
-
Escudier, B.1
Choueiri, T.K.2
Oudard, S.3
Szczylik, C.4
Negrier, S.5
Ravaud, A.6
Chevreau, C.7
Venner, P.8
Champagne, P.9
Croteau, D.10
-
96
-
-
84859828707
-
Resampling phase III data to assess phase II trial designs and endpoints
-
Sharma, M.R.; Karrison, T.G.; Jin, Y.; Bies, R.R.; Maitland, M.L.; Stadler, W.M.; Ratain, M.J. Resampling phase III data to assess phase II trial designs and endpoints. Clin. Cancer Res. 2012, 18, 2309-2315.
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 2309-2315
-
-
Sharma, M.R.1
Karrison, T.G.2
Jin, Y.3
Bies, R.R.4
Maitland, M.L.5
Stadler, W.M.6
Ratain, M.J.7
-
97
-
-
84855319445
-
Shark cartilage: Has the popularisation of science failed?
-
Alifrangis, C.; Stebbing, J. Shark cartilage: Has the popularisation of science failed? Lancet Oncol. 2012, 13, 22-22.
-
(2012)
Lancet Oncol.
, vol.13
, pp. 22-22
-
-
Alifrangis, C.1
Stebbing, J.2
-
98
-
-
84867278918
-
The antiangiogenic compound aeroplysinin-1 induces apoptosis in endothelial cells by activating the mitochondrial pathway
-
Martinez-Poveda, B.; Rodriguez-Nieto, S.; Garcia-Caballero, M.; Medina, M.A.; Quesada, A.R. The antiangiogenic compound aeroplysinin-1 induces apoptosis in endothelial cells by activating the mitochondrial pathway. Mar. Drugs 2012, 10, 2033-2046.
-
(2012)
Mar. Drugs
, vol.10
, pp. 2033-2046
-
-
Martinez-Poveda, B.1
Rodriguez-Nieto, S.2
Garcia-Caballero, M.3
Medina, M.A.4
Quesada, A.R.5
-
99
-
-
0031690667
-
Synthesis and biological evaluation of aeroplysinin analogues: A new class of receptor tyrosine kinase inhibitors
-
Hinterding, K.; Knebel, A.; Herrlich, P.; Waldmann, H. Synthesis and biological evaluation of aeroplysinin analogues: A new class of receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. 1998, 6, 1153-1162.
-
(1998)
Bioorg. Med. Chem.
, vol.6
, pp. 1153-1162
-
-
Hinterding, K.1
Knebel, A.2
Herrlich, P.3
Waldmann, H.4
-
100
-
-
77957991639
-
Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration
-
Sallam, A.A.; Ramasahayam, S.; Meyer, S.A.; Sayed, K.A. Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration. Bioorg. Med. Chem. 2010, 18, 7446-7457.
-
(2010)
Bioorg. Med. Chem.
, vol.18
, pp. 7446-7457
-
-
Sallam, A.A.1
Ramasahayam, S.2
Meyer, S.A.3
Sayed, K.A.4
-
101
-
-
17044420935
-
Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects
-
Tong, Y.G.; Zhang, X.W.; Tian, F.; Yi, Y.H.; Xu, Q.Z.; Li, L.; Tong, L.J.; Lin, L.P.; Ding, J. Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. Int. J. Cancer 2005, 114, 843-853.
-
(2005)
Int. J. Cancer
, vol.114
, pp. 843-853
-
-
Tong, Y.G.1
Zhang, X.W.2
Tian, F.3
Yi, Y.H.4
Xu, Q.Z.5
Li, L.6
Tong, L.J.7
Lin, L.P.8
Ding, J.9
-
102
-
-
25144483915
-
A new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo
-
Tian, F.; Zhang, X.W.; Tong, Y.G.; Yi, Y.; Zhang, S.L.; Li, L.; Sun, P.; Lin, L.P.; Ding, J. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. Cancer Biol. Ther. 2005, 4, 874-882.
-
(2005)
Cancer Biol. Ther.
, vol.4
, pp. 874-882
-
-
Tian, F.1
Zhang, X.W.2
Tong, Y.G.3
Yi, Y.4
Zhang, S.L.5
Li, L.6
Sun, P.7
Lin, L.P.8
Ding, J.P.E.9
-
103
-
-
79953767989
-
A one-pot synthesis and biological activity of ageladine a and analogues
-
Shengule, S.R.; Loa-Kum-Cheung, W.L.; Parish, C.R.; Blairvacq, M.; Meijer, L.; Nakao, Y.; Karuso, P. A one-pot synthesis and biological activity of ageladine a and analogues. J. Med. Chem. 2011, 54, 2492-2503.
-
(2011)
J. Med. Chem.
, vol.54
, pp. 2492-2503
-
-
Shengule, S.R.1
Loa-Kum-Cheung, W.L.2
Parish, C.R.3
Blairvacq, M.4
Meijer, L.5
Nakao, Y.6
Karuso, P.7
-
104
-
-
34447328084
-
Synthesis and matrix metalloproteinase (MMP)-12 inhibitory activity of ageladine A and its analogs
-
Ando, N.; Terashima, S. Synthesis and matrix metalloproteinase (MMP)-12 inhibitory activity of ageladine A and its analogs. Bioorg. Med. Chem. Lett. 2007, 17, 4495-4499.
-
(2007)
Bioorg. Med. Chem. Lett.
, vol.17
, pp. 4495-4499
-
-
Ando, N.1
Terashima, S.2
-
105
-
-
34250898546
-
Application of a 6pi-1-azatriene electrocyclization strategy to the total synthesis of the marine sponge metabolite ageladine A and biological evaluation of synthetic analogues
-
Meketa, M.L.; Weinreb, S.M.; Nakao, Y.; Fusetani, N. Application of a 6pi-1-azatriene electrocyclization strategy to the total synthesis of the marine sponge metabolite ageladine A and biological evaluation of synthetic analogues. J. Org. Chem. 2007, 72, 4892-4899.
-
(2007)
J. Org. Chem.
, vol.72
, pp. 4892-4899
-
-
Meketa, M.L.1
Weinreb, S.M.2
Nakao, Y.3
Fusetani, N.4
-
106
-
-
33748944826
-
Concise total synthesis of the marine natural product ageladine A
-
Shengule, S.R.; Karuso, P. Concise total synthesis of the marine natural product ageladine A. Org. Lett. 2006, 8, 4083-4084.
-
(2006)
Org. Lett.
, vol.8
, pp. 4083-4084
-
-
Shengule, S.R.1
Karuso, P.2
-
107
-
-
33645919009
-
Total synthesis of ageladine A, an angiogenesis inhibitor from the marine sponge Agelas nakamurai
-
Meketa, M.L.; Weinreb, S.M. Total synthesis of ageladine A, an angiogenesis inhibitor from the marine sponge Agelas nakamurai. Org. Lett. 2006, 8, 1443-1446.
-
(2006)
Org. Lett.
, vol.8
, pp. 1443-1446
-
-
Meketa, M.L.1
Weinreb, S.M.2
-
108
-
-
0345733986
-
Bioactive marine metabolites, Part 124. Ageladine A: An antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai
-
Fujita, M.; Nakao, Y.; Matsunaga, S.; Seiki, M.; Itoh, Y.; Yamashita, J.; van Soest, R.W.M.; Fusetani, N. Bioactive marine metabolites, Part 124. Ageladine A: An antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai. J. Am. Chem. Soc. 2003, 125, 15700-15701.
-
(2003)
J. Am. Chem. Soc.
, vol.125
, pp. 15700-15701
-
-
Fujita, M.1
Nakao, Y.2
Matsunaga, S.3
Seiki, M.4
Itoh, Y.5
Yamashita, J.6
Van Soest, R.W.M.7
Fusetani, N.8
-
109
-
-
84865413276
-
Incorporated nematocysts in Aeolidiella stephanieae (Gastropoda, Opisthobranchia, Aeolidoidea) mature by acidification shown by the pH sensitive fluorescing alkaloid Ageladine A
-
Obermann, D.; Bickmeyer, U.; Wagele, H. Incorporated nematocysts in Aeolidiella stephanieae (Gastropoda, Opisthobranchia, Aeolidoidea) mature by acidification shown by the pH sensitive fluorescing alkaloid Ageladine A. Toxicon 2012, 60, 1108-1116.
-
(2012)
Toxicon
, vol.60
, pp. 1108-1116
-
-
Obermann, D.1
Bickmeyer, U.2
Wagele, H.3
-
110
-
-
84856262141
-
The alkaloid Ageladine A, originally isolated from marine sponges, used for pH-sensitive imaging of transparent marine animals
-
Bickmeyer, U. The alkaloid Ageladine A, originally isolated from marine sponges, used for pH-sensitive imaging of transparent marine animals. Mar. Drugs 2012, 10, 223-233.
-
(2012)
Mar. Drugs
, vol.10
, pp. 223-233
-
-
Bickmeyer, U.1
-
111
-
-
33749008541
-
Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis
-
Zhao, H.J.; Liu, H.Y.; Chen, Y.; Xin, X.L.; Li, J.; Hou, Y.T.; Zhang, Z.H.; Zhang, X.W.; Me, C.Y.; Geng, M.Y.; et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res. 2006, 66, 8779-8787.
-
(2006)
Cancer Res
, vol.66
, pp. 8779-8787
-
-
Zhao, H.J.1
Liu, H.Y.2
Chen, Y.3
Xin, X.L.4
Li, J.5
Hou, Y.T.6
Zhang, Z.H.7
Zhang, X.W.8
Me, C.Y.9
Geng, M.Y.10
-
112
-
-
56849098340
-
The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo
-
Ma, J.G.; Xin, X.L.; Meng, L.H.; Tong, L.J.; Lin, L.P.; Geng, M.Y.; Ding, J. The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo. PLoS One 2008, 3, e3774.
-
(2008)
PLoS One
, vol.3
-
-
Ma, J.G.1
Xin, X.L.2
Meng, L.H.3
Tong, L.J.4
Lin, L.P.5
Geng, M.Y.6
Ding, J.7
-
113
-
-
0041854298
-
Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent α6 overexpression
-
Chabut, D.; Fischer, A.M.; Colliec-Jouault, S.; Laurendeau, I.; Matou, S.; Le Bonniec, B.; Helley, D. Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent α6 overexpression. Mol. Pharmacol. 2003, 64, 696-702.
-
(2003)
Mol. Pharmacol.
, vol.64
, pp. 696-702
-
-
Chabut, D.1
Fischer, A.M.2
Colliec-Jouault, S.3
Laurendeau, I.4
Matou, S.5
Le Bonniec, B.6
Helley, D.7
-
114
-
-
33845995846
-
Low molecular weight fucoidan increases VEGF(165)-induced endothelial cell migration by enhancing VEGF(165) binding to VEGFR-2 and NRP1
-
Lake, A.C.; Vassy, R.; Di Benedetto, M.; Lavigne, D.; Le Visage, C.; Perret, G.Y.; Letourneur, D. Low molecular weight fucoidan increases VEGF(165)-induced endothelial cell migration by enhancing VEGF(165) binding to VEGFR-2 and NRP1. J. Biol. Chem. 2006, 281, 37844-37852.
-
(2006)
J. Biol. Chem.
, vol.281
, pp. 37844-37852
-
-
Lake, A.C.1
Vassy, R.2
Di Benedetto, M.3
Lavigne, D.4
Le Visage, C.5
Perret, G.Y.6
Letourneur, D.7
-
115
-
-
0037380038
-
Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia
-
Luyt, C.E.; Meddahi-Pelle, A.; Ho-Tin-Noe, B.; Colliec-Jouault, S.; Guezennec, J.; Louedec, L.; Prats, H.E.; Jacob, M.P.; Osborne-Pellegrin, M.; Letourneur, D.; et al. Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. J. Pharmacol. Exp. Ther. 2003, 305, 24-30.
-
(2003)
J. Pharmacol. Exp. Ther.
, vol.305
, pp. 24-30
-
-
Luyt, C.E.1
Meddahi-Pelle, A.2
Ho-Tin-Noe, B.3
Colliec-Jouault, S.4
Guezennec, J.5
Louedec, L.6
Prats, H.E.7
Jacob, M.P.8
Osborne-Pellegrin, M.9
Letourneur, D.10
-
116
-
-
23044495371
-
Effects of middle molecular weight fucoidans on in vitro and ex vivo angiogenesis of endothelial cells
-
Matsubara, K.; Xue, C.; Zhao, X.; Mori, M.; Sugawara, T.; Hirata, T. Effects of middle molecular weight fucoidans on in vitro and ex vivo angiogenesis of endothelial cells. Int. J. Mol. Med. 2005, 15, 695-699.
-
(2005)
Int. J. Mol. Med.
, vol.15
, pp. 695-699
-
-
Matsubara, K.1
Xue, C.2
Zhao, X.3
Mori, M.4
Sugawara, T.5
Hirata, T.6
-
117
-
-
34447333662
-
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds
-
Cumashi, A.; Ushakova, N.A.; Preobrazhenskaya, M.E.; D'Incecco, A.; Piccoli, A.; Totani, L.; Tinari, N.; Morozevich, G.E.; Berman, A.E.; Bilan, M.I.; et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology 2007, 17, 541-552.
-
(2007)
Glycobiology
, vol.17
, pp. 541-552
-
-
Cumashi, A.1
Ushakova, N.A.2
Preobrazhenskaya, M.E.3
D'Incecco, A.4
Piccoli, A.5
Totani, L.6
Tinari, N.7
Morozevich, G.E.8
Berman, A.E.9
Bilan, M.I.10
-
118
-
-
0034595587
-
Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: Its possible mechanism of action
-
Soeda, S.; Kozako, T.; Iwata, K.; Shimeno, H. Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: Its possible mechanism of action. Biochim. Biophys. Acta 2000, 1497, 127-134.
-
(2000)
Biochim. Biophys. Acta
, vol.1497
, pp. 127-134
-
-
Soeda, S.1
Kozako, T.2
Iwata, K.3
Shimeno, H.4
-
119
-
-
0037437728
-
Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities
-
Koyanagi, S.; Tanigawa, N.; Nakagawa, H.; Soeda, S.; Shimeno, H. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem. Pharmacol. 2003, 65, 173-179.
-
(2003)
Biochem. Pharmacol.
, vol.65
, pp. 173-179
-
-
Koyanagi, S.1
Tanigawa, N.2
Nakagawa, H.3
Soeda, S.4
Shimeno, H.5
-
120
-
-
23244434817
-
Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed Sargassum stenophyllum
-
Dias, P.F.; Siqueira, J.M.; Vendruscolo, L.F.; Neiva, T.D.; Gagliardi, A.R.; Maraschin, M.; Ribeiro-do-Valle, R.M. Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed Sargassum stenophyllum. Cancer Chemother. Pharmacol. 2005, 56, 436-446.
-
(2005)
Cancer Chemother. Pharmacol.
, vol.56
, pp. 436-446
-
-
Dias, P.F.1
Siqueira, J.M.2
Vendruscolo, L.F.3
Neiva, T.D.4
Gagliardi, A.R.5
Maraschin, M.6
Ribeiro-Do-Valle, R.M.7
-
121
-
-
33846948975
-
A new marine-derived sulfated polysaccharide from brown alga suppresses tumor metastasis both in vitro and in vivo
-
Tang, X.L.; Li, J.; Xin, X.L.; Geng, M.Y. A new marine-derived sulfated polysaccharide from brown alga suppresses tumor metastasis both in vitro and in vivo. Cancer Biol. Ther. 2006, 5, 1474-1480.
-
(2006)
Cancer Biol. Ther.
, vol.5
, pp. 1474-1480
-
-
Tang, X.L.1
Li, J.2
Xin, X.L.3
Geng, M.Y.4
-
122
-
-
0038188599
-
Two new xanthone derivatives from the algicolous marine fungus Wardomyces anomalus
-
Abdel-Lateff, A.; Klemke, C.; Konig, G.M.; Wright, A.D. Two new xanthone derivatives from the algicolous marine fungus Wardomyces anomalus. J. Nat. Prod. 2003, 66, 706-708.
-
(2003)
J. Nat. Prod.
, vol.66
, pp. 706-708
-
-
Abdel-Lateff, A.1
Klemke, C.2
Konig, G.M.3
Wright, A.D.4
-
123
-
-
79960565525
-
Arthrinins A-D: Novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp
-
Ebada, S.S.; Schulz, B.; Wray, V.; Totzke, F.; Kubbutat, M.H.G.; Muller, W.E.G.; Hamacher, A.; Kassack, M.U.; Lin, W.H.; Proksch, P. Arthrinins A-D: Novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp. Bioorg. Med. Chem. 2011, 19, 4644-4651.
-
(2011)
Bioorg. Med. Chem.
, vol.19
, pp. 4644-4651
-
-
Ebada, S.S.1
Schulz, B.2
Wray, V.3
Totzke, F.4
Kubbutat, M.H.G.5
Muller, W.E.G.6
Hamacher, A.7
Kassack, M.U.8
Lin, W.H.9
Proksch, P.10
-
124
-
-
77951615481
-
Antiangiogenic metabolites from a marine-derived fungus, Hypocrea vinosa
-
Ohkawa, Y.; Miki, K.; Suzuki, T.; Nishio, K.; Sugita, T.; Kinoshita, K.; Takahashi, K.; Koyama, K. Antiangiogenic metabolites from a marine-derived fungus, Hypocrea vinosa. J. Nat. Prod. 2010, 73, 579-582.
-
(2010)
J. Nat. Prod.
, vol.73
, pp. 579-582
-
-
Ohkawa, Y.1
Miki, K.2
Suzuki, T.3
Nishio, K.4
Sugita, T.5
Kinoshita, K.6
Takahashi, K.7
Koyama, K.8
-
125
-
-
33845582571
-
Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy
-
Patel, S.; Keohan, M.L.; Saif, M.W.; Rushing, D.; Baez, L.; Feit, K.; DeJager, R.; Anderson, S. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006, 107, 2881-2887.
-
(2006)
Cancer
, vol.107
, pp. 2881-2887
-
-
Patel, S.1
Keohan, M.L.2
Saif, M.W.3
Rushing, D.4
Baez, L.5
Feit, K.6
Dejager, R.7
Anderson, S.8
-
126
-
-
33846041131
-
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy
-
Riely, G.J.; Gadgeel, S.; Rothman, I.; Saidman, B.; Sabbath, K.; Feit, K.; Kris, M.G.; Rizvi, N.A. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 2007, 55, 181-185.
-
(2007)
Lung Cancer
, vol.55
, pp. 181-185
-
-
Riely, G.J.1
Gadgeel, S.2
Rothman, I.3
Saidman, B.4
Sabbath, K.5
Feit, K.6
Kris, M.G.7
Rizvi, N.A.8
-
127
-
-
0034901968
-
Phase i trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer
-
Logothetis, C.J.; Wu, K.K.; Finn, L.D.; Daliani, D.; Figg, W.; Ghaddar, H.; Gutterman, J.U. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 2001, 7, 1198-1203.
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 1198-1203
-
-
Logothetis, C.J.1
Wu, K.K.2
Finn, L.D.3
Daliani, D.4
Figg, W.5
Ghaddar, H.6
Gutterman, J.U.7
-
128
-
-
32944463899
-
Angiogenesis
-
Folkman, J. Angiogenesis. Annu. Rev. Med. 2006, 57, 1-18.
-
(2006)
Annu. Rev. Med.
, vol.57
, pp. 1-18
-
-
Folkman, J.1
-
129
-
-
0141566695
-
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
-
Herbst, R.S.; Hammond, L.A.; Carbone, D.P.; Tran, H.T.; Holroyd, K.J.; Desai, A.; Williams, J.I.; Bekele, B.N.; Hait, H.; Allgood, V.; et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2003, 9, 4108-4115.
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 4108-4115
-
-
Herbst, R.S.1
Hammond, L.A.2
Carbone, D.P.3
Tran, H.T.4
Holroyd, K.J.5
Desai, A.6
Williams, J.I.7
Bekele, B.N.8
Hait, H.9
Allgood, V.10
-
130
-
-
12944249449
-
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
-
Varterasian, M.L.; Mohammad, R.M.; Shurafa, M.S.; Hulburd, K.; Pemberton, P.A.; Rodriguez, D.H.; Spadoni, V.; Eilender, D.S.; Murgo, A.; Wall, N.; et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin. Cancer Res. 2000, 6, 825-828.
-
(2000)
Clin. Cancer Res.
, vol.6
, pp. 825-828
-
-
Varterasian, M.L.1
Mohammad, R.M.2
Shurafa, M.S.3
Hulburd, K.4
Pemberton, P.A.5
Rodriguez, D.H.6
Spadoni, V.7
Eilender, D.S.8
Murgo, A.9
Wall, N.10
-
131
-
-
0034254971
-
A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma
-
Pagliaro, L.; Daliani, D.; Amato, R.; Tu, S.M.; Jones, D.; Smith, T.; Logothetis, C.; Millikan, R. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 2000, 89, 615-618.
-
(2000)
Cancer
, vol.89
, pp. 615-618
-
-
Pagliaro, L.1
Daliani, D.2
Amato, R.3
Tu, S.M.4
Jones, D.5
Smith, T.6
Logothetis, C.7
Millikan, R.8
-
132
-
-
0035139097
-
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer
-
Zonder, J.A.; Shields, A.F.; Zalupski, M.; Chaplen, R.; Heilbrun, L.K.; Arlauskas, P.; Philip, P.A. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin. Cancer Res. 2001, 7, 38-42.
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 38-42
-
-
Zonder, J.A.1
Shields, A.F.2
Zalupski, M.3
Chaplen, R.4
Heilbrun, L.K.5
Arlauskas, P.6
Philip, P.A.7
-
133
-
-
0035099740
-
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
-
Blackhall, F.H.; Ranson, M.; Radford, J.A.; Hancock, B.W.; Soukop, M.; McGown, A.T.; Robbins, A.; Halbert, G.; Jayson, G.C.; Comm, C.R.; et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br. J. Cancer 2001, 84, 465-469.
-
(2001)
Br. J. Cancer
, vol.84
, pp. 465-469
-
-
Blackhall, F.H.1
Ranson, M.2
Radford, J.A.3
Hancock, B.W.4
Soukop, M.5
McGown, A.T.6
Robbins, A.7
Halbert, G.8
Jayson, G.C.9
Comm, C.R.10
-
134
-
-
0035035103
-
Phase II evaluation of bryostatin-1 in metastatic melanoma
-
Bedikian, A.Y.; Plager, C.; Stewart, J.R.; O'Brian, C.A.; Herdman, S.K.; Ross, M.; Papadopoulos, N.; Eton, O.; Ellerhorst, J.; Smith, T. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res. 2001, 11, 183-188.
-
(2001)
Melanoma Res
, vol.11
, pp. 183-188
-
-
Bedikian, A.Y.1
Plager, C.2
Stewart, J.R.3
O'Brian, C.A.4
Herdman, S.K.5
Ross, M.6
Papadopoulos, N.7
Eton, O.8
Ellerhorst, J.9
Smith, T.10
-
135
-
-
0034851019
-
Phase II study of bryostatin 1 in patients with relapsed multiple myeloma
-
Varterasian, M.L.; Pemberton, P.A.; Hulburd, K.; Rodriguez, D.H.; Murgo, A.; Al-Katib, A.M. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Invest. New Drugs 2001, 19, 245-247.
-
(2001)
Invest. New Drugs
, vol.19
, pp. 245-247
-
-
Varterasian, M.L.1
Pemberton, P.A.2
Hulburd, K.3
Rodriguez, D.H.4
Murgo, A.5
Al-Katib, A.M.6
-
136
-
-
0034851020
-
Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer
-
Brockstein, B.; Samuels, B.; Humerickhouse, R.; Arietta, R.; Fishkin, P.; Wade, J.; Sosman, J.; Vokes, E.E. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest. New Drugs 2001, 19, 249-254.
-
(2001)
Invest. New Drugs
, vol.19
, pp. 249-254
-
-
Brockstein, B.1
Samuels, B.2
Humerickhouse, R.3
Arietta, R.4
Fishkin, P.5
Wade, J.6
Sosman, J.7
Vokes, E.E.8
-
137
-
-
0036210351
-
A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
-
Pfister, D.G.; McCaffrey, J.; Zahalsky, A.J.; Schwartz, G.K.; Lis, E.; Gerald, W.; Huvos, A.; Shah, J.; Kraus, D.; Shaha, A.; et al. A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Invest. New Drugs 2002, 20, 123-127.
-
(2002)
Invest. New Drugs
, vol.20
, pp. 123-127
-
-
Pfister, D.G.1
McCaffrey, J.2
Zahalsky, A.J.3
Schwartz, G.K.4
Lis, E.5
Gerald, W.6
Huvos, A.7
Shah, J.8
Kraus, D.9
Shaha, A.10
-
138
-
-
0036829335
-
A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study
-
Tozer, R.G.; Burdette-Radoux, S.; Berlanger, K.; Davis, M.L.; Lohmann, R.C.; Rusthoven, J.R.; Wainman, N.; Zee, B.; Seymour, L. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs 2002, 20, 407-412.
-
(2002)
Invest. New Drugs
, vol.20
, pp. 407-412
-
-
Tozer, R.G.1
Burdette-Radoux, S.2
Berlanger, K.3
Davis, M.L.4
Lohmann, R.C.5
Rusthoven, J.R.6
Wainman, N.7
Zee, B.8
Seymour, L.9
-
139
-
-
12244275670
-
Weekly bryostatin-1 in metastatic renal cell carcinoma: A phase II study
-
Haas, N.B.; Smith, M.; Lewis, N.; Littman, L.; Yeslow, G.; Joshi, I.D.; Murgo, A.; Bradley, J.; Gordon, R.; Wang, H.; et al. Weekly bryostatin-1 in metastatic renal cell carcinoma: A phase II study. Clin. Cancer Res. 2003, 9, 109-114.
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 109-114
-
-
Haas, N.B.1
Smith, M.2
Lewis, N.3
Littman, L.4
Yeslow, G.5
Joshi, I.D.6
Murgo, A.7
Bradley, J.8
Gordon, R.9
Wang, H.10
-
140
-
-
0037312095
-
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer
-
Winegarden, J.D.; Mauer, A.M.; Gajewski, T.F.; Hoffman, P.C.; Krauss, S.; Rudin, C.M.; Vokes, E.E. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 2003, 39, 191-196.
-
(2003)
Lung Cancer
, vol.39
, pp. 191-196
-
-
Winegarden, J.D.1
Mauer, A.M.2
Gajewski, T.F.3
Hoffman, P.C.4
Krauss, S.5
Rudin, C.M.6
Vokes, E.E.7
-
141
-
-
0242298228
-
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
-
Clamp, A.R.; Blackhall, F.H.; Vasey, P.; Soukop, M.; Coleman, R.; Halbert, G.; Robson, L.; Jayson, G.C. A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br. J. Cancer 2003, 89, 1152-1154.
-
(2003)
Br. J. Cancer
, vol.89
, pp. 1152-1154
-
-
Clamp, A.R.1
Blackhall, F.H.2
Vasey, P.3
Soukop, M.4
Coleman, R.5
Halbert, G.6
Robson, L.7
Jayson, G.C.8
-
142
-
-
0242491493
-
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
-
Madhusudan, S.; Protheroe, A.; Propper, D.; Han, C.; Corrie, P.; Earl, H.; Hancock, B.; Vasey, P.; Turner, A.; Balkwill, F.; et al. A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. Br. J. Cancer 2003, 89, 1418-1422.
-
(2003)
Br. J. Cancer
, vol.89
, pp. 1418-1422
-
-
Madhusudan, S.1
Protheroe, A.2
Propper, D.3
Han, C.4
Corrie, P.5
Earl, H.6
Hancock, B.7
Vasey, P.8
Turner, A.9
Balkwill, F.10
-
143
-
-
0345283114
-
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study
-
Armstrong, D.K.; Blessing, J.A.; Look, K.Y.; Schilder, R.; Nunez, E.R. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study. Invest. New Drugs 2003, 21, 373-377.
-
(2003)
Invest. New Drugs
, vol.21
, pp. 373-377
-
-
Armstrong, D.K.1
Blessing, J.A.2
Look, K.Y.3
Schilder, R.4
Nunez, E.R.5
-
144
-
-
1642452915
-
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
-
Armstrong, D.K.; Blessing, J.A.; Rader, J.; Sorosky, J.I. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Invest. New Drugs 2003, 21, 453-457.
-
(2003)
Invest. New Drugs
, vol.21
, pp. 453-457
-
-
Armstrong, D.K.1
Blessing, J.A.2
Rader, J.3
Sorosky, J.I.4
-
145
-
-
33646582949
-
A randomized phase II trial of interleukin-2 in combination with four
-
Peterson, A.C.; Harlin, H.; Karrison, T.; Vogelzang, N.J.; Knost, J.A.; Kugler, J.W.; Lester, E.; Vokes, E.; Gajewski, T.F.; Stadler, W.M. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest. New Drugs 2006, 24, 141-149.
-
(2006)
Invest. New Drugs
, vol.24
, pp. 141-149
-
-
Peterson, A.C.1
Harlin, H.2
Karrison, T.3
Vogelzang, N.J.4
Knost, J.A.5
Kugler, J.W.6
Lester, E.7
Vokes, E.8
Gajewski, T.F.9
Stadler, W.M.10
-
146
-
-
33646501280
-
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
-
Ajani, J.A.; Jiang, Y.; Faust, J.; Chang, B.B.; Ho, L.; Yao, J.C.; Rousey, S.; Dakhil, S.; Cherny, R.C.; Craig, C.; Bleyer, A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest. New Drugs 2006, 24, 353-357.
-
(2006)
Invest. New Drugs
, vol.24
, pp. 353-357
-
-
Ajani, J.A.1
Jiang, Y.2
Faust, J.3
Chang, B.B.4
Ho, L.5
Yao, J.C.6
Rousey, S.7
Dakhil, S.8
Cherny, R.C.9
Craig, C.10
Bleyer, A.11
-
147
-
-
49749093093
-
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
-
Ku, G.Y.; Ilson, D.H.; Schwartz, L.H.; Capanu, M.; O'Reilly, E.; Shah, M.A.; Kelsen, D.P.; Schwartz, G.K. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother. Pharmacol. 2008, 62, 875-880.
-
(2008)
Cancer Chemother. Pharmacol.
, vol.62
, pp. 875-880
-
-
Ku, G.Y.1
Ilson, D.H.2
Schwartz, L.H.3
Capanu, M.4
O'Reilly, E.5
Shah, M.A.6
Kelsen, D.P.7
Schwartz, G.K.8
-
148
-
-
67749124516
-
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant
-
Barr, P.M.; Lazarus, H.M.; Cooper, B.W.; Schluchter, M.D.; Panneerselvam, A.; Jacobberger, J.W.; Hsu, J.W.; Janakiraman, N.; Simic, A.; Dowlati, A.; et al. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am. J. Hematol. 2009, 84, 484-487.
-
(2009)
Am. J. Hematol.
, vol.84
, pp. 484-487
-
-
Barr, P.M.1
Lazarus, H.M.2
Cooper, B.W.3
Schluchter, M.D.4
Panneerselvam, A.5
Jacobberger, J.W.6
Hsu, J.W.7
Janakiraman, N.8
Simic, A.9
Dowlati, A.10
-
149
-
-
77951078231
-
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma
-
Lam, A.P.; Sparano, J.A.; Vinciguerra, V.; Ocean, A.J.; Christos, P.; Hochster, H.; Camacho, F.; Goel, S.; Mani, S.; Kaubisch, A. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am. J. Clin. Oncol. 2010, 33, 121-124.
-
(2010)
Am. J. Clin. Oncol.
, vol.33
, pp. 121-124
-
-
Lam, A.P.1
Sparano, J.A.2
Vinciguerra, V.3
Ocean, A.J.4
Christos, P.5
Hochster, H.6
Camacho, F.7
Goel, S.8
Mani, S.9
Kaubisch, A.10
-
150
-
-
84862295855
-
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium study
-
Morgan, R.J., Jr.; Leong, L.; Chow, W.; Gandara, D.; Frankel, P.; Garcia, A.; Lenz, H.J.; Doroshow, J.H. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium study. Invest. New Drugs 2012, 30, 723-728.
-
(2012)
Invest. New Drugs
, vol.30
, pp. 723-728
-
-
Morgan Jr., R.J.1
Leong, L.2
Chow, W.3
Gandara, D.4
Frankel, P.5
Garcia, A.6
Lenz, H.J.7
Doroshow, J.H.8
-
151
-
-
0036667939
-
The clinical development of the bryostatins
-
Clamp, A.; Jayson, G.C. The clinical development of the bryostatins. Anticancer Drugs 2002, 13, 673-683.
-
(2002)
Anticancer Drugs
, vol.13
, pp. 673-683
-
-
Clamp, A.1
Jayson, G.C.2
-
152
-
-
0035984562
-
The chemistry and biology of the bryostatin antitumour macrolides
-
Hale, K.J.; Hummersone, M.G.; Manaviazar, S.; Frigerio, M. The chemistry and biology of the bryostatin antitumour macrolides. Nat. Prod. Rep. 2002, 19, 413-453.
-
(2002)
Nat. Prod. Rep.
, vol.19
, pp. 413-453
-
-
Hale, K.J.1
Hummersone, M.G.2
Manaviazar, S.3
Frigerio, M.4
-
153
-
-
81055149914
-
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma
-
Hideshima, T.; Richardson, P.G.; Anderson, K.C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 2011, 10, 2034-2042.
-
(2011)
Mol. Cancer Ther.
, vol.10
, pp. 2034-2042
-
-
Hideshima, T.1
Richardson, P.G.2
Anderson, K.C.3
-
154
-
-
84875790116
-
-
accessed on 1 February 2013
-
ClinicalTrials.gov. Available on line: http://clinicaltrials.gov/ct2/ results?term=panobinostat&Search=Search (accessed on 1 February 2013).
-
-
-
-
155
-
-
79960197509
-
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma
-
Hainsworth, J.D.; Infante, J.R.; Spigel, D.R.; Arrowsmith, E.R.; Boccia, R.V.; Burris, H.A. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 2011, 29, 451-455.
-
(2011)
Cancer Invest.
, vol.29
, pp. 451-455
-
-
Hainsworth, J.D.1
Infante, J.R.2
Spigel, D.R.3
Arrowsmith, E.R.4
Boccia, R.V.5
Burris, H.A.6
-
156
-
-
84155164476
-
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome
-
Dimicoli, S.; Jabbour, E.; Borthakur, G.; Kadia, T.; Estrov, Z.; Yang, H.; Kelly, M.; Pierce, S.; Kantarjian, H.; Garcia-Manero, G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am. J. Hematol. 2012, 87, 127-129.
-
(2012)
Am. J. Hematol.
, vol.87
, pp. 127-129
-
-
Dimicoli, S.1
Jabbour, E.2
Borthakur, G.3
Kadia, T.4
Estrov, Z.5
Yang, H.6
Kelly, M.7
Pierce, S.8
Kantarjian, H.9
Garcia-Manero, G.10
-
157
-
-
84862878624
-
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
-
Wolf, J.L.; Siegel, D.; Goldschmidt, H.; Hazell, K.; Bourquelot, P.M.; Bengoudifa, B.R.; Matous, J.; Vij, R.; de Magalhaes-Silverman, M.; Abonour, R.; et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk. Lymphoma 2012, 53, 1820-1823.
-
(2012)
Leuk. Lymphoma
, vol.53
, pp. 1820-1823
-
-
Wolf, J.L.1
Siegel, D.2
Goldschmidt, H.3
Hazell, K.4
Bourquelot, P.M.5
Bengoudifa, B.R.6
Matous, J.7
Vij, R.8
De Magalhaes-Silverman, M.9
Abonour, R.10
-
158
-
-
84862895569
-
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
-
Offidani, M.; Polloni, C.; Cavallo, F.; Liberati, A.M.; Ballanti, S.; Pulini, S.; Catarini, M.; Alesiani, F.; Corvatta, L.; Gentili, S.; et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk. Lymphoma 2012, 53, 1722-1727.
-
(2012)
Leuk. Lymphoma
, vol.53
, pp. 1722-1727
-
-
Offidani, M.1
Polloni, C.2
Cavallo, F.3
Liberati, A.M.4
Ballanti, S.5
Pulini, S.6
Catarini, M.7
Alesiani, F.8
Corvatta, L.9
Gentili, S.10
-
159
-
-
84863339591
-
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy
-
Wang, H.B.; Cao, Q.; Dudek, A.Z. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012, 32, 1027-1031.
-
(2012)
Anticancer Res
, vol.32
, pp. 1027-1031
-
-
Wang, H.B.1
Cao, Q.2
Dudek, A.Z.3
-
160
-
-
84864024420
-
Panobinostat in patients with relapsed/refractory Hodgkin's Lymphoma after autologous stem-cell transplantation: Results of a phase II study
-
Younes, A.; Sureda, A.; Ben-Yehuda, D.; Zinzani, P.L.; Ong, T.C.; Prince, H.M.; Harrison, S.J.; Kirschbaum, M.; Johnston, P.; Gallagher, J.; et al. Panobinostat in patients with relapsed/refractory Hodgkin's Lymphoma after autologous stem-cell transplantation: Results of a phase II study. J. Clin. Oncol. 2012, 30, 2197-2203.
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 2197-2203
-
-
Younes, A.1
Sureda, A.2
Ben-Yehuda, D.3
Zinzani, P.L.4
Ong, T.C.5
Prince, H.M.6
Harrison, S.J.7
Kirschbaum, M.8
Johnston, P.9
Gallagher, J.10
-
161
-
-
84872107995
-
Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
-
Duvic, M.; Dummer, R.; Becker, J.C.; Poulalhon, N.; Ortiz Romero, P.; Grazia Bernengo, M.; Lebbe, C.; Assaf, C.; Squier, M.; Williams, D.; et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. Eur. J. Cancer 2013, 49, 386-394.
-
(2013)
Eur. J. Cancer
, vol.49
, pp. 386-394
-
-
Duvic, M.1
Dummer, R.2
Becker, J.C.3
Poulalhon, N.4
Ortiz Romero, P.5
Grazia Bernengo, M.6
Lebbe, C.7
Assaf, C.8
Squier, M.9
Williams, D.10
-
162
-
-
84874401753
-
Results of the phase II trial of single agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
-
Ghobrial, I.M.; Campigotto, F.; Murphy, T.J.; Boswell, E.N.; Banwait, R.; Azab, F.; Chuma, S.; Kunsman, J.; Donovan, A.; Masood, F.; et al. Results of the phase II trial of single agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood 2013, 121, 1296-1303.
-
(2013)
Blood
, vol.121
, pp. 1296-1303
-
-
Ghobrial, I.M.1
Campigotto, F.2
Murphy, T.J.3
Boswell, E.N.4
Banwait, R.5
Azab, F.6
Chuma, S.7
Kunsman, J.8
Donovan, A.9
Masood, F.10
-
163
-
-
84866358085
-
A phase i trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
-
Jones, S.F.; Infante, J.R.; Thompson, D.S.; Mohyuddin, A.; Bendell, J.C.; Yardley, D.A.; Burris, H.A., III. A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother. Pharmacol. 2012, 70, 471-475.
-
(2012)
Cancer Chemother. Pharmacol.
, vol.70
, pp. 471-475
-
-
Jones, S.F.1
Infante, J.R.2
Thompson, D.S.3
Mohyuddin, A.4
Bendell, J.C.5
Yardley, D.A.6
Burris III, H.A.7
-
164
-
-
84866554939
-
Phase i study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
-
Strickler, J.H.; Starodub, A.N.; Jia, J.; Meadows, K.L.; Nixon, A.B.; Dellinger, A.; Morse, M.A.; Uronis, H.E.; Marcom, P.K.; Zafar, S.Y.; et al. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother. Pharmacol. 2012, 70, 251-258.
-
(2012)
Cancer Chemother. Pharmacol.
, vol.70
, pp. 251-258
-
-
Strickler, J.H.1
Starodub, A.N.2
Jia, J.3
Meadows, K.L.4
Nixon, A.B.5
Dellinger, A.6
Morse, M.A.7
Uronis, H.E.8
Marcom, P.K.9
Zafar, S.Y.10
-
165
-
-
67449127082
-
Clinical studies of histone deacetylase inhibitors
-
Prince, H.M.; Bishton, M.J.; Harrison, S.J. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 2009, 15, 3958-3969.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 3958-3969
-
-
Prince, H.M.1
Bishton, M.J.2
Harrison, S.J.3
-
166
-
-
84856752960
-
Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab
-
Barboza, N.M.; Medina, D.J.; Budak-Alpdogan, T.; Aracil, M.; Jimeno, J.M.; Bertino, J.R.; Banerjee, D. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biol. Ther. 2012, 13, 114-122.
-
(2012)
Cancer Biol. Ther.
, vol.13
, pp. 114-122
-
-
Barboza, N.M.1
Medina, D.J.2
Budak-Alpdogan, T.3
Aracil, M.4
Jimeno, J.M.5
Bertino, J.R.6
Banerjee, D.7
-
167
-
-
79959697959
-
Plitidepsin has a safe cardiac profile: A comprehensive analysis
-
Soto-Matos, A.; Szyldergemajn, S.; Extremera, S.; Miguel-Lillo, B.; Alfaro, V.; Coronado, C.; Lardelli, P.; Roy, E.; Corrado, C.S.; Kahatt, C. Plitidepsin has a safe cardiac profile: A comprehensive analysis. Mar. Drugs 2011, 9, 1007-1023.
-
(2011)
Mar. Drugs
, vol.9
, pp. 1007-1023
-
-
Soto-Matos, A.1
Szyldergemajn, S.2
Extremera, S.3
Miguel-Lillo, B.4
Alfaro, V.5
Coronado, C.6
Lardelli, P.7
Roy, E.8
Corrado, C.S.9
Kahatt, C.10
-
168
-
-
84856213732
-
A phase i and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study
-
Geoerger, B.; Estlin, E.J.; Aerts, I.; Kearns, P.; Gibson, B.; Corradini, N.; Doz, F.; Lardelli, P.; Miguel, B.D.; Soto, A.; et al. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study. Eur. J. Cancer 2012, 48, 289-296.
-
(2012)
Eur. J. Cancer
, vol.48
, pp. 289-296
-
-
Geoerger, B.1
Estlin, E.J.2
Aerts, I.3
Kearns, P.4
Gibson, B.5
Corradini, N.6
Doz, F.7
Lardelli, P.8
Miguel, B.D.9
Soto, A.10
-
169
-
-
63049135328
-
Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma
-
Schoffski, P.; Guillem, V.; Garcia, M.; Rivera, F.; Tabernero, J.; Cullell, M.; Lopez-Martin, J.A.; Pollard, P.; Dumez, H.; del Muro, X.G.; et al. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar. Drugs 2009, 7, 57-70.
-
(2009)
Mar. Drugs
, vol.7
, pp. 57-70
-
-
Schoffski, P.1
Guillem, V.2
Garcia, M.3
Rivera, F.4
Tabernero, J.5
Cullell, M.6
Lopez-Martin, J.A.7
Pollard, P.8
Dumez, H.9
Del Muro, X.G.10
-
170
-
-
36749071496
-
Aplidine: A paradigm of how to handle the activity and toxicity of a novel marine anticancer poison
-
Le Tourneau, C.; Raymond, E.; Faivre, S. Aplidine: A paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr. Pharm. Des. 2007, 13, 3427-3439.
-
(2007)
Curr. Pharm. Des.
, vol.13
, pp. 3427-3439
-
-
Le Tourneau, C.1
Raymond, E.2
Faivre, S.3
-
171
-
-
1942452836
-
Progress in the clinical development of new marine-derived anticancer compounds
-
Jimeno, J.; Lopez-Martin, J.A.; Ruiz-Casado, A.; Izquierdo, M.A.; Scheuer, P.J.; Rinehart, K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 2004, 15, 321-329.
-
(2004)
Anticancer Drugs
, vol.15
, pp. 321-329
-
-
Jimeno, J.1
Lopez-Martin, J.A.2
Ruiz-Casado, A.3
Izquierdo, M.A.4
Scheuer, P.J.5
Rinehart, K.6
-
172
-
-
76749105187
-
Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma
-
Baudin, E.; Droz, J.P.; Paz-Ares, L.; van Oosterom, A.T.; Cullell-Young, M.; Schlumberger, M. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. Am. J. Clin. Oncol. 2010, 33, 83-88.
-
(2010)
Am. J. Clin. Oncol.
, vol.33
, pp. 83-88
-
-
Baudin, E.1
Droz, J.P.2
Paz-Ares, L.3
Van Oosterom, A.T.4
Cullell-Young, M.5
Schlumberger, M.6
-
173
-
-
67650687006
-
Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma
-
Eisen, T.; Thomas, J.; Miller, W.H.; Gore, M.; Wolter, P.; Kavan, P.; Martin, J.A. L.; Lardelli, P. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res. 2009, 19, 185-192.
-
(2009)
Melanoma Res
, vol.19
, pp. 185-192
-
-
Eisen, T.1
Thomas, J.2
Miller, W.H.3
Gore, M.4
Wolter, P.5
Kavan, P.6
Martin, J.A.L.7
Lardelli, P.8
-
174
-
-
61749103952
-
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer
-
Eisen, T.; Thatcher, N.; Leyvraz, S.; Miller, W.H.; Couture, F.; Lorigan, P.; Luthi, F.; Small, D.; Tanovic, A.; O'Brien, M. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer 2009, 64, 60-65.
-
(2009)
Lung Cancer
, vol.64
, pp. 60-65
-
-
Eisen, T.1
Thatcher, N.2
Leyvraz, S.3
Miller, W.H.4
Couture, F.5
Lorigan, P.6
Luthi, F.7
Small, D.8
Tanovic, A.9
O'Brien, M.10
-
175
-
-
44449104653
-
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
-
Peschel, C.; Hartmann, J.T.; Schmittel, A.; Bokemeyer, C.; Schneller, F.; Keilholz, U.; Buchheidt, D.; Millan, S.; Izquierdo, M.A.; Hofheinz, R.D. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 2008, 60, 374-380.
-
(2008)
Lung Cancer
, vol.60
, pp. 374-380
-
-
Peschel, C.1
Hartmann, J.T.2
Schmittel, A.3
Bokemeyer, C.4
Schneller, F.5
Keilholz, U.6
Buchheidt, D.7
Millan, S.8
Izquierdo, M.A.9
Hofheinz, R.D.10
-
176
-
-
84874527310
-
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
-
Ribrag, V.; Caballero, D.; Ferme, C.; Zucca, E.; Arranz, R.; Briones, J.; Gisselbrecht, C.; Salles, G.; Gianni, A.M.; Gomez, H.; et al. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica 2012, 98, 357-363.
-
(2012)
Haematologica
, vol.98
, pp. 357-363
-
-
Ribrag, V.1
Caballero, D.2
Ferme, C.3
Zucca, E.4
Arranz, R.5
Briones, J.6
Gisselbrecht, C.7
Salles, G.8
Gianni, A.M.9
Gomez, H.10
-
177
-
-
77953722666
-
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
-
Mateos, M.V.; Cibeira, M.T.; Richardson, P.G.; Prosper, F.; Oriol, A.; de la Rubia, J.; Lahuerta, J.J.; Garcia-Sanz, R.; Extremera, S.; Szyldergemajn, S.; et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin. Cancer Res. 2010, 16, 3260-3269.
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 3260-3269
-
-
Mateos, M.V.1
Cibeira, M.T.2
Richardson, P.G.3
Prosper, F.4
Oriol, A.5
De La Rubia, J.6
Lahuerta, J.J.7
Garcia-Sanz, R.8
Extremera, S.9
Szyldergemajn, S.10
-
178
-
-
64749088834
-
Emerging treatments for multiple myeloma: Beyond immunomodulatory drugs and bortezomib
-
Mitsiades, C.S.; Hideshima, T.; Chauhan, D.; McMillin, D.W.; Klippel, S.; Laubach, J.P.; Munshi, N.C.; Anderson, K.C.; Richardson, P.G. Emerging treatments for multiple myeloma: Beyond immunomodulatory drugs and bortezomib. Semin. Hematol. 2009, 46, 166-175.
-
(2009)
Semin. Hematol.
, vol.46
, pp. 166-175
-
-
Mitsiades, C.S.1
Hideshima, T.2
Chauhan, D.3
McMillin, D.W.4
Klippel, S.5
Laubach, J.P.6
Munshi, N.C.7
Anderson, K.C.8
Richardson, P.G.9
-
179
-
-
84871407100
-
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
-
Millward, M.; Price, T.; Townsend, A.; Sweeney, C.; Spencer, A.; Sukumaran, S.; Longenecker, A.; Lee, L.; Lay, A.; Sharma, G.; et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest. New Drugs 2012, 30, 2303-2317.
-
(2012)
Invest. New Drugs
, vol.30
, pp. 2303-2317
-
-
Millward, M.1
Price, T.2
Townsend, A.3
Sweeney, C.4
Spencer, A.5
Sukumaran, S.6
Longenecker, A.7
Lee, L.8
Lay, A.9
Sharma, G.10
-
180
-
-
68949095188
-
First-in-human phase i study of the novel structure proteasome inhibitor NPI-0052
-
Hamlin, P.A.; Aghajanian, C.; Younes, A.; Hong, D.S.; Palladino, M.A.; Longenecker, A.M.; Lloyd, G.K.; Hannah, A.L.; Spear, M.A.; Kurzrock, R. First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052. J. Clin. Oncol. 2009, 27, 3516.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3516
-
-
Hamlin, P.A.1
Aghajanian, C.2
Younes, A.3
Hong, D.S.4
Palladino, M.A.5
Longenecker, A.M.6
Lloyd, G.K.7
Hannah, A.L.8
Spear, M.A.9
Kurzrock, R.10
-
181
-
-
77949432502
-
Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)
-
Hofmeister, C.C.; Richardson, P.; Zimmerman, T.; Spear, M.A.; Palladino, M.A.; Longenecker, A.M.; Cropp, G.F.; Lloyd, G.K.; Hannah, A.L.; Anderson, K. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM). J. Clin. Oncol. 2009, 27, 8505.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 8505
-
-
Hofmeister, C.C.1
Richardson, P.2
Zimmerman, T.3
Spear, M.A.4
Palladino, M.A.5
Longenecker, A.M.6
Cropp, G.F.7
Lloyd, G.K.8
Hannah, A.L.9
Anderson, K.10
-
182
-
-
64749095133
-
Phase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma
-
Richardson, P.; Hofmeister, C.C.; Zimmerman, T.M.; Chanan-Khan, A.A.; Spear, M.A.; Palladino, M.A.; Longenecker, A.M.; Cropp, G.; Lloyd, G.K.; Wear, S.; et al. Phase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma. Blood 2008, 112, 955-956.
-
(2008)
Blood
, vol.112
, pp. 955-956
-
-
Richardson, P.1
Hofmeister, C.C.2
Zimmerman, T.M.3
Chanan-Khan, A.A.4
Spear, M.A.5
Palladino, M.A.6
Longenecker, A.M.7
Cropp, G.8
Lloyd, G.K.9
Wear, S.10
-
183
-
-
84872172060
-
New proteasome inhibitors in myeloma
-
Lawasut, P.; Chauhan, D.; Laubach, J.; Hayes, C.; Fabre, C.; Maglio, M.; Mitsiades, C.; Hideshima, T.; Anderson, K.C.; Richardson, P.G. New proteasome inhibitors in myeloma. Curr. Hematol. Malig. Rep. 2012, 7, 258-266.
-
(2012)
Curr. Hematol. Malig. Rep.
, vol.7
, pp. 258-266
-
-
Lawasut, P.1
Chauhan, D.2
Laubach, J.3
Hayes, C.4
Fabre, C.5
Maglio, M.6
Mitsiades, C.7
Hideshima, T.8
Anderson, K.C.9
Richardson, P.G.10
-
184
-
-
78650376933
-
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
-
Mita, M.M.; Spear, M.A.; Yee, L.K.; Mita, A.C.; Heath, E.I.; Papadopoulos, K.P.; Federico, K.C.; Reich, S.D.; Romero, O.; Malburg, L.; et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin. Cancer Res. 2010, 16, 5892-5899.
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 5892-5899
-
-
Mita, M.M.1
Spear, M.A.2
Yee, L.K.3
Mita, A.C.4
Heath, E.I.5
Papadopoulos, K.P.6
Federico, K.C.7
Reich, S.D.8
Romero, O.9
Malburg, L.10
|